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Anxiety disorder can negatively affect many areas of a child’s life, including social and 
academic development, and increase the risk of mental health problems in adolescence and 
adulthood. Although psychotherapy is an effective treatment for children with anxiety, it is 
not widely available, while psychiatric medications are recommended for use in only the 
most severe cases. For these reasons, investigation into other possible treatments for 
problems with anxiety is necessary. The present study examined the effect of a broad-based 
micronutrient formula called EMPowerplus (EMP+) on children suffering from elevated 
levels of anxiety, following a multiple baseline design. The final sample comprised 14 
participants, aged between eight and 12 years, who were randomised into one of three 
baseline groups, ranging from one to three weeks in length. Following the baseline period, 
participants took part in an open-label trial of EMP+ for eight weeks, after which a three-
month follow-up was conducted. Although there was a trend toward a decrease in symptom 
severity over the baseline period, there was a much greater decline in symptoms during the 
intervention phase. Modified Brinley plots revealed decreases in anxiety and improvements 
in overall functioning for 10 out of 11 participants who completed the intervention. A 
comparison of group means confirmed statistically significant change between baseline and 
end of trial, while gains were maintained over the follow-up period. Furthermore, those 
participants who were compliant with the intervention tended to improve more than 
participants who were not compliant and side effects were generally mild and transient.  This 
study provides evidence for the potential of micronutrient interventions in effectively treating 
anxiety in children. It also opens the door for future research utilising placebo-controlled 
designs, as well as comparisons to other conventional treatments.





1.1  Anxiety in Children 
Anxiety itself is an adaptive response, the effect of stimulation of the sympathetic 
nervous system. It allows the body to prepare to respond to danger, meaning anxiety is often 
an appropriate reaction to a threatening or dangerous situation. Everybody will at some point 
feel anxious, although it might be described as something else, for instance feeling ‘stressed 
out’ or ‘uptight’(Bushnell et al., 1998). Stimulation of the sympathetic nervous system 
produces nervous and endocrine system changes resulting in a rapid and generalised 
response, the fight-or-flight response. The physiological changes which occur because of this 
response allow an individual to attack, run from or freeze in the face of a threat and can 
include tachycardia, increased perspiration, tremor, increased blood glucose concentrations, 
constriction of blood vessels, slowing of non-essential systems such as digestion and the 
immune system, pupil dilation, muscle tension and an increase in breathing rate (Fraser & 
Solovey, 2007). As part of this psychophysiological response, the hypothalamic-pituitary-
adrenal (HPA) axis is activated to release norepinephrine and cortisol into the bloodstream 
(Tufnell & DeJong, 2009). The overall response allows the body to cope with the source of 
the stress and anxiety over a period of time, and then gradually return to normal functioning 
after a stressor is removed. 
However, the response can also be triggered in situations where there is perceived 
threat rather than real threat, or when the threat has long passed. Indeed, in today’s society 
many threats cannot be resolved through fighting or fleeing. Instead these modern threats are 
often long-lasting or recurrent and allow the individual little control over removal of the 
threat, resulting in continuous or repeated activation of the body’s stress systems (Bushnell et 
al., 1998). This could be likened to continual activation of the freeze response, when an 
animal has no option but to endure the threat and hope for survival. In such situations as 




these, anxiety can often become chronic, resulting in impairment in learning through 
deficiencies in memory and concentration, and difficulties at home and with peers due to 
behavioural repercussions,  such as impaired affect modulation and impulse control. This 
chronic anxiety can have negative physical effects on the body such as causing persistent 
gastrointestinal issues or headaches, weakening of the immune system, generally higher 
disease burden and even impaired brain development (Gruner, 2006; Sparrow, 2007). In 
adults, high levels of anxiety or stress have been linked to increased risk of cardiovascular 
incidents and stroke (Gruner, 2006). Anxiety itself, as well as its secondary effects, can cause 
a great deal of distress for a child and can be amplified when the child expects further 
stressful stimuli. The child can end up in a vicious circle whereby distress continues to 
increase anxiety, impairing performance, having more negative effects on the child’s life and 
thus, increasing distress (Sparrow, 2007). Alleviating anxiety disorder once it occurs will 
allow a child to grow and learn unhindered by chronic anxiety’s negative effects and prevent 
anxiety affecting the child’s life as they move into adolescence and adulthood.  
Anxiety and stress in childhood is often a natural, common and short-lived experience 
with the presentation varying according to the individual’s developmental stage (Barrett, 
2000). A number of younger children experience separation anxiety, while a common source 
of anxiety for older children can be school and tests (Beidel & Alfano, 2011; Vallance & 
Garralda, 2008). Dealing with stress and anxiety successfully teaches children coping skills 
they can use and develop throughout life, yet much of the literature acknowledges our 
understanding of anxiety in children is limited (Albano, Chorpita, & Barlow, 2003).  
In some cases the natural fears and anxieties of childhood can be the precursor for 
more serious and debilitating illness (Beidel & Alfano, 2011). Once anxiety rises to levels 
that interfere with social, emotional and/or academic development, is culturally or 
developmentally inappropriate, or causes a child or his/her family significant distress, then 




anxiety is seen as a disorder (American Psychiatric Association, 2013), a problem for the 
child which is likely to lead to further issues. Anxiety disorders are some of the most 
common psychiatric illnesses affecting children (Albano, Chorpita, & Barlow, 2003). 
Chronically high levels of anxiety are associated with significant impairment and often result 
in avoidance of activities including socialising and educational and recreational opportunities 
(Albano et al., 2003), ultimately interfering with development.  
Research suggests significant anxiety can develop at an early age. Spence, Rapee, 
McDonald and Ingram (2001) found anxiety symptoms consistent with DSM-IV diagnostic 
categories present in a sample of children aged 2.5 to 6.5 years. Furthermore, there is 
evidence that anxiety disorder in childhood is predictive of psychiatric symptomatology as 
children move into adolescence (Achenbach, Howell, McConaughy, & Stanger, 1995) and 
later into adulthood (Ferdinand & Verhulst, 1995), whether specific to continued anxiety 
symptoms or other classifications of psychopathology. For instance, high anxiety in 
childhood has been found to result in increased risk of further anxiety disorder or depressive 
disorders in later life (Rockhill et al., 2010). Other evidence suggests, if left untreated or for 
those who respond less favourably to treatment, childhood anxiety disorders can lead to 
adverse outcomes and further psychiatric illness in adolescence, such as substance abuse 
(Kendall, Safford, Flannery-Schroeder, & Webb, 2004).  
Individuals with high anxiety or an anxiety disorder have specific reoccurring fears or 
worries in relation to certain situations, or have anxiety symptoms which may seem to appear 
unexpectedly, such as in panic disorder. Symptoms of anxiety disorder may present as 
behavioural and somatic symptomatology, including tantrums, being easily startled, ritualistic 
behaviour, avoidance (e.g. of situations or places), sleep disturbance, tearfulness, changes in 
eating patterns, school refusal, chest or abdominal pain, gastrointestinal symptoms, 
headaches, nausea, muscle tension, restlessness, body aches and sweating. Anxiety disorder 




also presents in the form of emotional and cognitive symptoms such as worries, expecting the 
worst, difficulty concentrating, feeling helpless and distress (Bushnell et al., 1998; Kelly, 
2005). 
Community prevalence rates for all anxiety disorders range from 3.1% to 17.5% in 
children and adolescents (Rockhill et al., 2010). In New Zealand, approximately 7% of 
children will meet criteria for any anxiety disorder at age 11 years. By 18 years of age, this 
number will be just below 20%. Anxiety disorders tend to be equally prevalent in boys and 
girls during childhood, after which girls are more likely to be diagnosed (Cohen et al., 1993). 
In addition, at least one third of children with an anxiety disorder will meet criteria for 
another one or more anxiety disorders (Strauss & Last, 1993). Brady and Kendall (1992) 
found comorbidity rates of anxiety and depression for children and adolescents ranged from 
16-62%, with anxiety tending to present earlier than depression.  
International data from the WHO International Consortium in Psychiatric 
Epidemiology (ICPE) found the age of onset for anxiety disorders was remarkably similar 
across a range of countries and that more than 50% of cases had their onset before the age of 
20 years (Lieb, 2005). Approximately 20% had their first onset before the age of 10 years 
(Lieb, 2005). Specific phobia and social phobia have been shown to have the earliest age of 
onset, usually in childhood or adolescence, while generalised anxiety disorder (GAD), 
obsessive compulsive disorder (OCD) and panic disorder tend to first occur in late 
adolescence or early adulthood (Burke, Burke, Regie, & Rae, 1990; Magee, Eaton, Wittchen, 
McGonagle, & Kessler, 1996; Wittchen, Lieb, Schuster, & Oldenhinkel, 1999a). 
While an initial anxiety disorder may remit, there is also a risk that another anxiety 
disorder may develop in childhood (Last, Perrin, Hersen, & Kazdin, 1996) or in adolescence 
(Aschenbrand, Kendall, Webb, Safford, & Flannery-Schroeder, 2003). In addition, the more 
severe the disorder, the greater the level of impairment and the more likely it is that the 




disorder will persist (Dadds et al., 1999; Manassis & Hood, 1998). Furthermore, children 
with anxiety disorders are at a greater risk of later being diagnosed with depression and 
substance abuse, not just other anxiety disorders (Connolly & Bernstein, 2007). These 
children are also at greater risk of experiencing educational underachievement, even after 
controlling for the confounding effects of socio-familial and individual factors (Woodward & 
Fergusson, 2001). 
Anxiety disorders can have wide reaching effects on a child’s development, including 
negative effects on social, family and academic functioning, as the symptoms of the disorders 
interfere with normal development in a number of areas (Connolly & Bernstein, 2007). This 
can have further effects on the child’s self-image, including low self-esteem and a tendency 
to interpret situations negatively (Bögels & Zigterman, 2000). As discussed, there is also a 
chance that anxiety during childhood will persist into adolescence and adulthood, resulting in 
additional psychiatric problems and further negatively affect the individual’s life. 
 
1.2 Treatments for Childhood Anxiety 
Pediatric anxiety disorders tend to be treatable conditions when prompt diagnosis is 
followed by prompt treatment, minimising the impact of anxiety on the individual and the 
family system (Kelly, 2005). Research suggests psychotherapy and pharmacotherapy are 
effective at reducing the symptoms of anxiety (Kelly, 2005). The intensity of treatment 
should be targeted to the severity of anxiety symptoms (Connolly & Bernstein, 2007). For 
instance, mild anxiety may be best treated with brief psychotherapy. However, more severe 
anxiety or moderate to severe anxiety which requires acute symptom reductions may require 
more intensive psychotherapy or a combination of psychotherapy and pharmacotherapy in 
order to reduce symptoms (Connolly & Bernstein, 2007; Kelly, 2005). It is not recommended 
that pharmacotherapy be the sole treatment for pediatric anxiety disorders unless there is no 




or little response to psychotherapy (Connolly & Bernstein, 2007). Indeed, many traditional 
medications are not recommended for use with children, either through lack of effect, adverse 
side effects or poor research methods and designs which result in inadequate conclusions 
(Kelly, 2005). It has been recommended that treatment be delivered by a multidisciplinary 
team and take a multimodal approach for optimal gains and resolution of anxiety (Connolly 
& Bernstein, 2007). In addition, a combination of therapies tailored to the individual and the 
family is most likely to relieve symptoms and improve quality of life (Ali, 2007). 
 
1.2.1 Psychotherapy. Psychological therapies used in the treatment of high anxiety 
and anxiety disorders often take the form of cognitive behavioural therapy (CBT; Ali, 2007). 
CBT is a highly adaptable therapy focusing primarily on the link between an individual’s 
thoughts, feelings and behaviour, but in which a number of different techniques can be 
incorporated to best fit the individual client and his/her symptomatology. Namely CBT for 
children with anxiety includes at least some of the following components: psychoeducation 
for parents and child, training in somatic symptom management skills, cognitive 
restructuring, teaching problem-solving and coping strategies, exposure tasks and relapse 
prevention (Albano & Kendall, 2002; Bernstein & Victor, 2007; Mor & Meijers, 2009). For 
example, exposure-based techniques are efficacious in treating certain types of anxiety such 
as phobias and can be readily integrated into a CBT framework (Compton et al., 2004). 
Furthermore, an emphasis should be put on monitoring and reducing functional impairment, 
not solely anxiety symptoms, as functional impairment can lead to further anxiety symptoms 
and other co-morbid disorders (Connolly & Bernstein, 2007). There is support for both the 
short-term and long-term effectiveness of CBT for the treatment of anxiety in children 
(Barrett, Duffy, Dadds, & Rapee, 2001; Kendall et al., 2004; Saavedra, Silverman, Morgan-
Lopez, & Kurtines, 2010); however, it is not universally effective, with 20-50% of children 




who have undergone CBT treatment still meeting criteria for an anxiety disorder following 
treatment (Kendall, 1994; Kendall et al., 1997). 
Another approach which is used in the treatment of childhood anxiety is 
psychodynamic psychotherapy. This approach lacks research on its efficacy or effectiveness; 
however, some studies have shown positive effects on anxiety symptomatology (Connolly & 
Bernstein, 2007). One disadvantage to psychodynamic psychotherapy is the length and 
intensity with which it is administered. Often clients will see a therapist two to three times a 
week for at least a few months, making this type of therapy less accessible and more costly 
than the more time-limited and weekly sessions traditionally seen within CBT. In addition, 
CBT can also be delivered in a group format, both to children and to parents, reducing costs 
and decreasing waitlists compared to individual treatment. Bernstein and Victor (2007) 
suggest including parents or caregivers in treatment to improve symptom reduction and 
provide support for the child outside of therapy in terms of learning and using the new skills  
being taught within therapy sessions. This is particularly useful for young children and for 
children with severe anxiety symptoms or comorbid diagnoses and also serves to address any 
maladaptive parenting styles or techniques which may be contributing to anxiety (Bernstein 
& Victor, 2007). Ultimately, psychotherapy can help children to learn how to manage and 
reduce anxiety to normal, adaptive levels. 
 
1.2.2 Pharmacotherapy. Selective Serotonin Reuptake Inhibitors (SSRIs) are the 
most common medication prescribed for the treatment of childhood anxiety disorders other 
than post-traumatic stress disorder (Bloch & Mc Guire, 2011; Connolly & Bernstein, 2007). 
A number of studies have demonstrated a significant decrease in anxiety symptoms with the 
treatment of SSRIs compared to placebo (e.g. Beidel et al., 2007; Birmaher et al., 2003; 




Rynn, Siqueland, & Rickels, 2001). As such, SSRIs are considered the first line 
pharmacotherapy treatment of choice for pediatric anxiety disorders (Watson, 2011). 
Studies have also investigated the effect of benzodiazepines on anxiety disorders in 
children and adolescents. In a review, Riddle et al. (1999) found that although overall there 
was a trend for improvement within the anxiety treatment groups, the studies were generally 
of short duration and there were high response rates within placebo groups. Furthermore, the 
authors recommended only short-term prescriptions given the risk of dependence and warned 
of the risk for reoccurrence of anxiety after ceasing drug treatment. Benzodiazepines, along 
with noradrenergic antidepressants and buspirone, are considered second or third-line 
pharmacotherapy alternatives (Watson, 2011). There is very little research supporting the use 
of noradrenergic antidepressants and buspirone in the treatment of paediatric anxiety 
disorders. 
National Institute of Health and Care Excellence (NICE) guidelines are internationally 
recognised and constitute a series of clinical guidelines to ensure consistent, high quality and 
evidence based care within the health sector. The NICE (2005) guidelines for treatment of 
depression in children and young people recommend that SSRI’s be used in the treatment of 
childhood depression only when: the depression is moderate to severe; after at least four to 
six sessions of an at least three month programme of a recommended psychological therapy 
in which there is no response; after psychological therapy for co-morbid difficulties or risk 
factors, additional psychological therapy for the child and perhaps psychological therapy for 
the parents and other family members in which there is no decrease in depression symptoms.  
Even then, fluoxetine should be offered to young people (aged 12-18 years) following 
specific treatment guidelines, and offered cautiously to children (aged 5-11 years) following 
the same treatment guidelines. In essence, the NICE guidelines indicate that antidepressant 
treatment should be the last treatment option for children and young people, except in the 




instance where there are moderate to severe depressive symptoms, significant risk issues and 
no response from four to six weeks of psychological therapy. SSRI’s should not be given for 
mild depression in children. 
Similar, if not more conservative recommendations, could be made for anxiety 
disorders in children, especially considering the lack of evidence for the use of SSRI’s for the 
treatment of anxiety disorders in this age group. Guidelines published by The Werry Centre 
for Child and Adolescent Mental Health Workforce Development suggest SSRI’s  only 
feature in the “promising treatment” category for OCD in children, but no other anxiety 
disorder (Dunnachie, 2007). Indeed, Fisher, Tobkes, Kotcher, and Masia-Warner (2006) 
assert that the US Federal Drug Association has not approved SSRI’s for the treatment of any 
child anxiety disorder, other than OCD.  
There is a relative lack of research into the use of psychiatric medications for anxiety 
treatment in children compared to the adult research literature. As such, it may be that with 
further research there is more evidence for using medication to treat anxiety disorders in 
children; however, the research on the use of medications for childhood anxiety is plagued by 
a large amount of controversy involving issues about poor research designs and methods, 
such as small sample sizes and short trial durations, high placebo response rates and 
publication biases (Riddle et al., 1999). There is also little research comparing medication 
with conventional treatments for anxiety (e.g. psychotherapy). One study by Beidel and 
colleagues (2007) compared Social Effectiveness Therapy (SET-C) to fluoxetine in a sample 
of 122 children and adolescents diagnosed with social phobia. They found both were more 
efficacious than placebo at reducing social distress and behavioural avoidance, as well as at 
increasing general functioning. However, SET-C was better than fluoxetine in terms of 
improvement in social anxiety, reducing behavioural avoidance and absence of social anxiety 




diagnosis at the end of the trial. In addition, the researchers found SET-C provided continued 
improvement over three months, whereas fluoxetine reached maximum effect by two months. 
Other criticisms of antidepressant research include the cost and benefit analysis when 
considering improvement rates for individuals taking medication compared to those on 
placebo, the number of participants who remain symptomatic and the side effects. Birmaher 
et al. (2003), using an intent-to-treat analysis, found 61% of participants on fluoxetine (SSRI) 
improved between much to very much, compared to 35% taking placebo. However, a 
significant group of those taking fluoxetine remained symptomatic despite improvement, 
while fluoxetine was also linked to mild and transient headaches and gastrointestinal 
symptoms. In this study, there were also instances of excitement, giddiness or disinhibition in 
seven participants taking fluoxetine and four participants taking placebo, with five of the 
fluoxetine participants having to discontinue the treatment. Another study investigating the 
effect of sertraline (SSRI) for anxiety found participants taking sertraline reported a greater 
number of adverse events than participants taking placebo, including more experiences of dry 
mouth, drowsiness, leg spasms and restlessness (Rynn, Siqueland, & Rickels, 2001).  
Similarly, Walkup and colleagues (2001) reported abdominal discomfort and increased motor 
activity were significantly more common in the group of participants taking fluvoxamine 
(SSRI) than in the placebo group.  Furthermore, no study has compared different types of 
SSRI’s with one another to determine which individuals these drugs might be most 
efficacious for, given, results suggest that SSRI’s may have different levels efficacy for 
different anxiety disorders (Fisher et al., 2006). For instance, Birmaher et al. (2003) found a 
greater treatment effect for children with social phobia compared to those with separation 
anxiety disorder when treating anxiety with fluoxetine. 
Some researchers and clinicians have argued there is an advantage for medication, in 
that it has a quicker therapeutic action than psychotherapies. However, although both Rynn et 




al. (2001) and Walkup et al. (2001) reported finding a trend towards improvement by week 
four of their trials, it took nine weeks on fluoxetine before this treatment became significantly 
better than placebo. This suggests that the usually recommended eight to 12 sessions of 
psychological therapy for these disorders, occurring weekly, will see an improvement in 
anxiety symptoms at an equal, if not quicker rate than medication, without the need for 
continued medication use and without side effects. In addition, psychological therapy teaches 
children ways to manage their anxiety, which given the association between childhood 
anxiety and later psychopathology, could possibly also reduce the seriousness of, or prevent, 
later mental health issues. 
Overall, SSRI’s are recommended for treatment of anxiety in the short-term, for those 
with whom psychotherapy has had little or no effect and for those who cannot access 
psychotherapy (Dunnachie, 2007; Fisher et al., 2006; Watson, 2011). Psychotherapy, 
particularly CBT, should be the first line treatment for children with anxiety disorders, 
although more research is necessary into both psychotherapy and medication treatments, in 
order to have a clearer picture of which treatments might be most appropriate and efficacious 
for certain individuals and the way in which these should be delivered. It is also important to 
note that some individuals prefer not to take medication to help control their mental illness, 
either because of the side effects or because they do not want to use drugs as matter of 
personal preference. Yet, psychotherapy may not be available to these individuals, as it is not 
usually publically funded for those with illness that is mild to moderate in severity, resulting 
in the exclusion of a significant number of people who suffer from anxiety. Furthermore, 
attending psychotherapy sessions privately can be costly, meaning this maybe not be an 
option for some individuals either. Thus, other treatments need to be explored to increase 
treatment accessibility and widen the range of choice for children and families suffering from 




anxiety disorders. Micronutrients may be another such treatment option. This will be 
explored in the following sections. 
 
1.3 Why Micronutrients Should Be Considered 
Micronutrients are the vitamins and minerals which allow the brain and body to 
function, making them necessary for physical and mental health. Micronutrients are essential 
for many aspects of brain functioning, including energy metabolism, synthesis of 
neurotransmitters and maintaining blood supply to brain tissue (Haller, 2005). In fact, blood 
supply to the brain has been found to be effected by long-term vitamin deficiency, which can 
lead to tissue death and other pathological processes affecting mental and physical health 
(Haller, 2005). The B vitamins are particularly important in this respect, with depletion 
associated with such syndromes as Wernicke’s and Korsakoff’s syndromes and 
neuropsychiatric symptoms, such as low mood and irritability (Haller, 2005).  Zinc and iron 
deficiencies have been implicated in some neurological degenerative disorders, such as 
Alzheimer’s disease (Bray & Levy, 2005; Pinero & Connor, 2005). Other micronutrients are 
important for brain development, including zinc for its role in cognitive development (Haller, 
2005) and iodine for its role in thyroid development (Lazarus, 2005). Deficiency of iodine 
prenatally can lead to increased stillbirths, infant mortality and congenital abnormalities, 
while deficiency of iodine in children and adults can lead to hypothyroidism and impaired 
mental functioning (Lazarus, 2005). Micronutrients serve as essential cofactors for 
neurotransmitter synthesis, with more than one third of enzymes needing a vitamin or mineral 
cofactor (Haller, 2005). Simply, without micronutrients survival would be impossible, let 
alone good health. 
The increase in mental health disorders which has been observed over the last few 
decades has been linked to the deterioration of the Western diet, which is characterised by 




high amounts of processed foods and a lack of fruits and vegetables, ultimately leading to 
micronutrient deficiencies (Lakhan & Vieira 2008; Jacka et al., 2010). This could be further 
compounded by the depletion in mineral content of soils due to agricultural practices (Mayer, 
1997), and thus of foods such as fruits and vegetables (Thomson & Robinson, 1980; Ekholm 
et al., 2007). As micronutrients have such a wide ranging and important role in normal brain 
functioning and have been implicated in a number of syndromes and disorders with 
psychiatric and behavioural effects, they are worthy of consideration within the field of 
mental health research. This would be even without knowledge of the link between an 
increase in mental health disorders and the Western diet deterioration. In addition, given 
anxiety disorders are such a debilitating illness, affecting such a number of individuals, any 
contribution to its treatment is worth pursuing. As Lakhan and Vieira (2010) acknowledge, 
the universality of nutritional and herbal remedies in many cultures over thousands of years 
makes this avenue an appropriate one to take. Furthermore, the side effects of some anti-
anxiety medications, the questionable effectiveness and efficacy of those medications, the 
lack of availability of psychotherapy and personal preference, all point towards exploring 
different types of treatment for anxiety. The research demonstrating the efficacy of 
micronutrients for treatment of some mental health disorders is growing, as is the research 
demonstrating the safety of micronutrient interventions and mild side effect profile.  
 
1.4 Theories about Micronutrient Deficiencies and Mental Health Symptoms 
There have been a number of theories proposed about the role of micronutrient 
deficiencies in mental health and the expression of psychiatric symptoms. Evidence suggests 
that the B-vitamins may be particularly important in terms of ameliorating symptoms of 
stress and anxiety (Camfield et al., 2013). Folate, B6 and B12, as well as some other B-
vitamins, are involved in a process whereby homocysteine is cleared from the body, through 




converting homocysteine back to methionine (Camfield et al., 2013). Homocysteine is 
produced during metabolism of methionine and methionine metabolism is important for the 
methylation of a number of substances, including DNA (Camfield et al., 2013). If 
homocysteine is not converted back to methionine, then some methylation processes cannot 
occur, despite methylation being a very important process within the brain. The large 
amounts of homocysteine that build up when it is not converted back to methionine have 
been found to cause oxidative stress and damage to DNA and mitochondrial membranes 
(Camfield et al., 2013). The link between increased homocysteine and stress has been 
demonstrated by Kang et al. (2005) and Stoney (1999).  
An effect on mood has also been implicated in this process. This is because 
methionine is required for the synthesis of S-adenosyl-methionine (SAMe; Bottiglieri, 1996). 
SAMe is required for a number of different reactions including the synthesis of 
neurotransmitters such as serotonin (Papakostas, Alpert and Fava, 2003). Many studies have 
linked folate and B12 deficiencies to mood via elevated plasma homocysteine and low SAMe 
levels, while treatment of depression with SAMe has had positive effects in open and 
randomised, controlled trials (Papakostas et al., 2003).  
It is well known that stress results in many physiological changes throughout the brain 
and body, including altering the gut’s ability to absorb nutrients (Kaplan et al., 2007). Thus, it 
is also important to note that stress and anxiety may impair the above methylation reactions 
via affecting nutrient absorption by the gut. Furthermore, inadequate absorption could have a 
negative flow-on effect to the nutrients required for neurotransmitter synthesis and therefore 
any processes or functions these neurotransmitters may be utilised in (Kaplan et al., 2007).  
Another proposed link between micronutrient deficiencies and the symptoms of 
mental illness is via inborn errors in metabolism. Ames (2004) demonstrated that at least one 
third of genetic mutations reduced the binding affinity of coenzymes. Suboptimal levels of 




coenzymes, of which include a number of micronutrients, would reduce rates of metabolic 
activity because of decreased binding rates (Kaplan & Leung, 2011). It may be that for some 
mental health disorders where there is significant heritability, the cause of the symptoms is 
due to inborn errors of metabolism which slow metabolic activity, such that micronutrient 
treatment might increase that activity (Kaplan and Leung, 2011).  
Mitochondrial dysfunction has also been implicated in the underlying 
pathophysiology of some disorders (Rucklidge & Kaplan, 2013). Mitochondrial dysfunction 
could negatively affect the energy metabolism of neurons and glial cells, thus affecting their 
ability to functioning optimally. This would compromise neurotransmitter synthesis and 
synaptic communication for instance (Rucklidge & Kaplan, 2013). Relatively new research 
suggests that ATP (the source of cellular energy created by mitochondria) manufacturing is 
reduced in bipolar disorder, attention-deficit hyperactivity disorder (ADHD) and other mental 
healthdisorders (Russell et al., 2006; Young 2007), with Gardner and Boles (2005) proposing 
a model which includes reduction in mitochondrial energy metabolism as one of the 
predisposing factors in certain chronic mental health problems. Young (2007), in an editorial 
in the Journal of Psychiatry and Neuroscience, discussed the potential role of impaired 
mitochondria in contributing to bipolar disorder. He argued that if energy metabolism is 
reduced, this may lead to subtle neural damage, which may be more evident in those who 
suffer from bipolar disorder and result in lasting cognitive impairment. A number of 
micronutrients are involved in the processes which create ATP, while traditional 
mitochondrial diseases are commonly treated with nutrients, rather than drugs (Rucklidge & 
Kaplan, 2013). 
Ames’s (2010) triage hypothesis proposes that our body naturally rebalances our 
metabolism when the availability of micronutrients is not at optimal levels, such that 
available micronutrients are directed towards those processes necessary for survival. This 




occurs at the expense of long-term health in some cases, eventually leading to degenerative 
disorders through the cumulative effects of nutrient deficiencies. This may be particularly 
relevant to those individuals who experience mental illness later in life (Kaplan et al., 2007). 
Another theory is that some mental illness may be caused by alterations in gene 
expression due to nutrient deficiency. It is well-established within the fields of nutrigeomics 
and epigenetics that nutrient status can alter genetic expression (Kaplan and Leung, 2011).  
Kaplan et al. (2007) acknowledge that, like all of these theories, this one overlaps with other 
theories but that different theories can be compatible. Nutrient deficiencies which alter gene 
expression could affect methylation processes for instance. 
While there are theories and evidence to suggest some possible routes for the effect 
that micronutrients may have on the brain and body, the biological evidence is still in its 
infancy. However, the biological explanations for some anxiety disorders themselves are also 
incomplete (Lakhan & Vieira, 2010). 
 
1.5 Research Specific to Anxiety and Stress: The Effect of Single Ingredient 
Interventions on Anxiety and Stress Symptoms 
Research has found evidence that single micronutrients can relieve symptoms of 
anxiety and stress in adults. A study by De Souza, Walker, Robinson & Bollard (2000) found 
a small effect of daily dietary supplementation with 200mg/day magnesium and 50mg/day 
vitamin B6 on decreasing premenstrual anxiety. A significant effect was not found when the 
participants consumed magnesium or vitamin B6 alone or when taking placebo, although 
these interventions did lead to a decrease in anxiety compared to baseline (De Souza et al., 
2000).  
Research has also examined the effects of selenium and thiamine (vitamin B1) on 
stress and anxiety.  A randomised, double-blind, placebo-controlled study of 63 participants 




taking 200mg/day selenium over 12 months found those participants taking selenium 
experienced significantly less anxiety compared to the placebo-treated participants (Shor-
Posner, et al., 2003). In a small study investigating the impact of daily 100mg thiamine on 
nine participants with GAD and low blood thiamine levels at baseline, the researchers found 
thiamine supplementation significantly improved scores on the Hamilton Anxiety Rating 
Scale, indicating this also decreased anxiety (Luong & Nguyen, 2011). Furthermore, the 
authors reported an increase in appetite and well-being, as well as a decrease in fatigue in 
those participants taking thiamine (Luong & Nguyen, 2011). 
Other studies have investigated the effect of compounds which are not vitamins or 
minerals on stress and anxiety. For instance, some research has investigated the effect of 
inositol. Inositol is a part of the intracellular phosphatidyl inositol second messenger system 
and a naturally occurring vitamin-like chemical found in a plants and animal tissue (Kofman, 
Einat, Cohen, Tenne & Shoshana, 2000). It has been linked to a number of neurotransmitter 
receptors, thus, the levels of this compound in the brain have the potential to alter 
neurotransmitter levels and synaptic communication (Mukai, Kishi, Matsuda & Iwata, 2014). 
Inositol supplementation is utilised in medicine for a range of reasons, such as treating 
respiratory distress syndrome in premature infants (Kofman, et al., 2000). Inositol has been 
shown to benefit patients with panic disorder and OCD. In a double-blind, placebo-controlled 
crossover study by Fux, Levine, Aviv and Belmaker (1996) 13 patients with OCD had 
significantly lower scores on the Yale-Brown Obsessive Compulsive Scale after taking 
18g/day of inositol for one month when compared to placebo. Another double-blind, placebo-
controlled, crossover design study investigated the impact of 12mg/day inositol on 21 
participants with Panic Disorder (with and without agoraphobia; Benjamin et al., 1995). This 
study found that both the frequency and severity of panic attacks decreased more with 
inositol administration than with placebo. There was also a significant decrease in the 




severity of agoraphobia following inositol administration compared to placebo (Benjamin et 
al., 1995). Furthermore, a double-blind, crossover study compared Hamilton Rating Scale for 
Anxiety scores for 20 participants with Panic Disorder who took inositol for one month 
versus those same participants after taking fluvoxamine for one month. No significant 
differences were found, although nausea and tiredness were more common with fluvoxamine, 
thus the authors concluded inositol may provide an attractive treatment for those cannot take 
or who prefer not to take psychiatric medication (Palatnik, Frolov, Fux, & Benjamin, 2001). 
Kava-kava, a preparation made from the plant Piper methysticum, has been utilised as 
a treatment for anxiety is a number of studies. The first randomised, placebo-controlled, 
double-blind study of kava-kava in relation to its anxiolytic effects was conducted with 101 
participants who had been diagnosed with an anxiety disorder. The researchers found 
participants who had been taking kava-kava over the 25 week trial period had an 
improvement in anxiety symptomatology above that of those taking placebo (Volz & Kieser, 
1997). These results have been replicated in a further five RCT’s, although another four 
RCT’s have found no such result (see Lakhan & Vieira, 2010). This suggests some potential 
efficacy of kava-kava but that more research into why there is inconsistency across studies 
should be conducted. There has been some concern over the safety of kava-kava 
supplements, as it was linked to the potential for severe liver damage. However, reviews 
investigating safety have found serious side effects may have occurred due to poor quality, 
overdose, prolonged use and use with other medications (Lakhan & Vieira, 2010). 
St John’s Wort has been investigated for its anxiolytic effects. Some research suggests 
that St John’s Wort may reduce anxiety in participants diagnosed with OCD, while other 
studies have found no such link. For instance, one open label study by Taylor and Kobak 
(2000) with 13 participants diagnosed with OCD found significant improvements in anxiety 
symptoms, comparable to those improvements seen with SSRI treatment. A randomised 




controlled trial of 60 participants diagnosed with OCD found no significant difference 
between the treatment group and placebo group after 12 weeks (Kobak et al., 2005). 
The effect of passionflower on anxiety has been investigated in a small number of 
studies, with evidence of an anxiolytic effect (Lakhan & Vieira, 2010). A double-blind, 
placebo-controlled study compared oxazepam and passionflower in a sample of 36 
participants diagnosed with GAD. The researchers found no significant difference between 
the two treatments, leading them to conclude that passionflower may be as effective as a 
traditional benzodiazepine in reducing anxiety symptomology (Akhondzadeh et al., 2001). 
A number of researchers have noted the contribution of individual vitamins, minerals 
or other compounds in the treatment of psychiatric symptoms (eg: Kaplan et al., 2007; 
Lakhan & Vieira, 2010). While there is evidence that at least some of these compounds have 
an anxiolytic effect, the effect is usually modest and inconsistent between studies (Rucklidge 
& Kaplan, 2013). As mentioned above, the body and brain require a number of different 
micronutrients to function optimally, thus multi-nutrient compounds are also worthy of 
investigation, as the combined effect of multiple nutrients may be more powerful than the 
effect of single nutrients. 
 
1.6 The Effect of Multi-Ingredient Interventions on Anxiety and Stress Symptoms 
Since the year 2000, the number of studies investigating the effect of nutrient 
interventions containing multiple ingredients has increased substantially (Kaplan & Leung, 
2011). This seems in direct contrast to the scientific method which guides quality modern 
research today. The scientific method holds that one single independent variable should be 
changed in an experiment so as to determine cause and effect, thus micronutrient formulas, 
with multiple different ingredients, have received criticism in the research literature for 
containing so many “independent variables” (Rucklidge and Kaplan, 2013). As Burford-




Mason (2009) reported, this concept as applied to nutrition, is problematic given the 
complexity of the human system and the way its physiology functions, while two decades ago 
Mertz (1994) acknowledged that the idea of “one-disease–one-nutrient” was outdated. Given 
humans require so many different nutrients and that the imbalance of nutrients can have a 
flow on effect to other nutrients, single-nutrient interventions might actually create 
deficiencies by disturbing homeostasis (Mertz, 1994). Pauling (1995) added to this position 
by stating that “biochemical and genetic arguments support the idea that orthomolecular 
therapy, the provision for the individual person of the optimum concentrations of important 
normal constituents of the brain, may be the preferred treatment for many mentally ill 
patients.” Multi-ingredient formulas allow for the molecular environment of the brain to be 
optimised when the amounts of nutrients needed for this to occur are above those provided by 
an individual’s diet or biological make-up (Pauling, 1995). Research using multi-ingredient 
micronutrient compounds in the treatment of stress and anxiety will now be reviewed.  
A number of studies have investigated the impact of high dose B vitamin formulas on 
stress and anxiety, including five randomised controlled trials. The B vitamin formulas also 
commonly contain other vitamins and minerals, but the main ingredients are B vitamins. One 
study investigated the effect of three months administration of ‘Blackmores Executive B 
Stress Formula’ in a typical form and in a sustained release form, compared to placebo in 80 
participants (Stough et al., 2011; 19 ingredients). After controlling for the effects of 
personality and individual work demands, the researchers found those participants in the 
treatment groups experienced significantly lower personal strain following the three month 
intervention than the placebo group, as well as a reduction in the tension-anxiety subscale of 
the Profile of Mood Scale (Stough et al., 2011). However, there was no treatment effect for 
anxiety as measured by the State-Trait Anxiety Inventory and no significant difference in 




treatment effect when comparing the typical and sustained release forms of the intervention 
(Stough et al., 2011).  
Four studies have investigated the effect of the same formula, Berocca™ (Bayer 
[Leverkusen, Germany]; 12 ingredients), on stress or anxiety, with positive results. Carroll, 
Ring, Suter and Willemsen (2000) investigated the effect of Berocca™ on the psychological 
well-being of 80 healthy, young males over 28 days in a double-blind, placebo-controlled 
trial. The researchers found that compared with placebo, those taking Berocca™ experienced 
significant reductions in anxiety and perceived stress, as well as improvements in tiredness 
and concentration. Another study also investigated the effect of Berocca™ on healthy males. 
Kennedy et al. (2010), in a double-blind, placebo-controlled trial of 215 males, reported that 
those taking Berocca™ experienced less perceived stress than those taking placebo after the 
33 day intervention.  
Another double-blind, placebo controlled study examining the impact of Berocca™ 
reported a significant difference in stress-related symptoms in those participants taking 
Berocca™ for one month, compared to those in the placebo group (Schlebusch et al., 2000). 
This study included a large sample of 300 participants, from two different centres.  
The final study investigating the effect of Berocca™ also investigated the effect of a 
micronutrient formula called CNE™, containing 36 ingredients, with vitamins, minerals, 
amino acids and antioxidants (Rucklidge et al., 2012). This was an unblinded study with 116 
participants and compared Berocca™ to two different doses of CNE and a non-randomised 
control group over four weeks following a large earthquake. All treatment groups 
experienced a significant reduction in anxiety, stress and earthquake-related distress when 
compared to the control group, while those taking the higher dose of the broader range 
formula experienced a greater benefit overall than those taking Berocca™ (Rucklidge et al., 
2012). 




Another study by Rucklidge and colleagues (2011) examined the impact of a 
micronutrient formula called EMPowerplus (EMP+), with the same ingredients as CNE, on 
stress and anxiety in 36 adults with ADHD.  Two weeks following a 7.1 earthquake in 
Christchurch, NZ, those participants taking EMP+ reported significantly less anxiety and 
stress symptoms than those participants not taking EMP+. These differences could not be 
explained by other variables, including age, gender, ethnicity, SES, IQ, baseline measures of 
emotions, or personal loss and damage following the earthquake (Rucklidge et al., 2011). 
Two case studies have been reported in the literature using micronutrients to treat 
anxiety. Both of these case studies investigated the impact of EMP+ on OCD symptoms in 
on-off designs. Rucklidge (2009) demonstrated control over anxiety and obsessions in an 
ABAB designed case study of an 18-year old male with OCD, who had previously undergone 
CBT for one year with a partial response, followed by a return to the severe anxiety range and 
development of major depression within another year. A case study by Kaplan, Crawford, 
Gardner and Farrelly (2002) on an eight year boy with atypical OCD (obsessions without 
discernible compulsions), ADHD, mood liability and explosive rage revealed significant 
reductions in obsessional thoughts, along with significant improvements in mood lability and 
an overall calmer demeanour and more well controlled temper. 
Haskell and colleagues (2010) examined the effect of a micronutrient formula on 
cognitive function and fatigue, as well as anxiety, in a sample of 216 healthy female 
participants following a placebo-controlled, double-blind, randomised study design. 
However, this study found no significant treatment effects in terms of anxiety when 
comparing the micronutrient and placebo treatment groups. It is important to note that many 
studies use healthy participants, thus authors are limited in their ability deduce much about 
the effect of micronutrients on anxiety symptoms which could be considered disorder.  




Long and Benton (2013) also investigated the impact of micronutrient 
supplementation in a large sample. These researchers utilised Centrum™ Advanced 50+ (25 
ingredients) and examined stress in a sample of 202 young adult men. They compared 
Centrum™ Advanced 50+ supplementation alone to supplementation with DHA fatty acids, 
supplementation with both Centrum™ Advanced 50+ and DHA fatty acids and placebo in a 
12 week double-blind, randomised trial. The researchers found a significant decrease in 
perceived stress in the micronutrient group when compared to placebo, but not in the DHA 
fatty acid only or combined group when compared to placebo (Long & Benton, 2013).  
An interesting study by Gruenwald, Graubaum and Harde (2002) studied the effect of 
a micronutrient formula which also contained probiotics over 6 months. This study found a 
significant reduction in stress and anxiety in 42 adults suffering from stress or exhaustion. 
Stress and anxiety are known to affect the health of the gastrointestinal system through 
affecting the absorption of nutrients and thus may lead to deficiencies. Also, chronic stress 
and anxiety can compromise intestinal flora, such that the intestines and colon can become 
damaged (Gruenwald et al., 2002). This is because of the constant arousal which occurs due 
to anxiety, leading to the release of adrenaline and other sympathetic nervous system 
functions including the diversion of blood from the intestines to the muscles. Depending on 
the type of bacteria present in the intestines and the dietary substances being ingested, toxic 
compounds can amass then exit the intestines through the damage in the intestinal lining, 
entering the bloodstream (Gruenwald et al., 2002).  Rucklidge and Kaplan (2013), in a recent 
expert review of broad-spectrum micronutrient formulas in the treatment of psychiatric 
symptoms, highlight the importance of the role that bacteria play in relation to the gut-brain 
connection. These authors suggest combining micronutrients with probiotics will be 
important in future research so as to optimise nutrient absorption and gut health, thus 
maximising treatment response. 




One study investigating the impact of micronutrients on anxiety in children, other 
than the above case studies, was found during the literature search. This study by Zhang et al. 
(2012) examined the impact of micronutrient supplementation (21 ingredients; formula name 
not specified by the authors) on anxiety in elementary school children living in rural China. 
Randomly selected schools were placed in either a control or treatment condition, with 2730 
students participating in total, taking the intervention for 36 weeks. The researchers found a 
significant reduction in anxiety in the treatment condition compared to the placebo condition. 
The above studies demonstrate the potential efficacy of micronutrients in the 
treatment of stress and anxiety, with one study and two case studies showing the 
effectiveness of micronutrient formulas at reducing anxiety in children (Kaplan et al., 2002; 
Rucklidge, 2009; Zhang et al., 2012). Two trials (Rucklidge et al., 2011; Rucklidge et al., 
2012) and two case studies (Kaplan et al., 2002; Rucklidge et al., 2009) utilised EMP+ or an 
equivalent formula in their research. This broad-spectrum formula has been widely used in 
research for a number of different psychiatric conditions and is the most researched of the 
above reviewed formulas. The research on EMP+ will be briefly reviewed in the following 
section. 
 
1.7 Literature on EMP+ 
EMP+ is a broad-spectrum micronutrient formula which contains 16 trace minerals, 
14 vitamins, three amino acids and three antioxidants. An ingredient list of EMP+ is included 
in Appendix A. David Hardy and Anthony Stephan created EMP+ based on Stephan’s 
agricultural knowledge about the treatment of aggression in livestock, initially for the 
treatment of bipolar disorder. Twenty-one articles have been published on the use of EMP+ 
for the treatment of psychiatric symptoms, including one systematic review of the safety and 
tolerability of the formula, randomised controlled trials and case studies.  




The formula itself has gone through three revisions. The first reduced the number of 
capsules needing to be taken to achieve the recommended dose from 32 to 15 capsules per 
day and occurred in November 2002, meaning research since this time has used the newer but 
equivalent formula. CNE is another formula equivalent to EMP+ which is marketed for the 
general population. The most recent revision created two further formulas which provide 
similar amounts of the same nutrients as EMP+, but are proposed to be easier on the gut for 
those who had gastrointestinal side effects with EMP+. These are Daily Essential Nutrients, 
which is marketed at individuals with mental or physical health difficulties, and Daily Self 
Defense™, which is marketed at the general population. EMP+ remains available at the time 
of writing and is also available in a powder form which can be mixed into liquid. 
Simpson and colleagues (2011) systematically reviewed the safety and tolerability of 
EMP+ for use within mental health given the formula is so widely used and the 
recommended dosage provides some ingredients at levels higher than recommended daily 
allowance. The researchers utilised data from both published and unpublished studies and 
found no abnormal blood tests or clinically meaningful negative outcomes due to toxicity. 
They found only minor and brief reports of headaches and nausea associated with the 
currently available version of EMP+ and concluded that these results were reassuring in 
terms of safety and tolerability. 
 
1.7.1 EMP+ and mood. Seven published studies have investigated the impact of 
EMP+ on bipolar disorder. Kaplan and colleagues (2001) utilised an open label design to 
examine the effect of EMP+ on the symptoms of bipolar disorder in 11 adults over six 
months. The researchers found the number of psychotropic medications the participants were 
on decreased with the intervention, while they also found a significant decrease in scores on 
measures assessing depression, mania and general psychiatric status, with large effect sizes 




for these primary measures. Eighty-six percent of participants were deemed responders, with 
at least a 20% reduction of symptoms on all three primary measures. In the same year, Popper 
(2001) trialled EMP+ with 22 children and adults who also had bipolar disorder. He found 19 
of those patients had a positive response, including 10 with marked improvement, while 11 
out of the 15 participants who had been on psychiatric medication when they began the trial, 
had been stable for six to nine months without medication. 
Simmons (2003) also investigated the effect of EMP+ on bipolar disorder using an 
open label design. He found clinical improvement in 16 participants out of a sample of 19 
adults with bipolar disorder taking EMP+ for between five and 21 months. Furthermore, 13 
participants who were on medication remained stable when the sole intervention was EMP+. 
Frazier, Fristad and Arnold (2012) examined the effect of EMP+ on bipolar spectrum 
disorders in 10 children over six and a half months. Seven children completed the study, with 
all completers experiencing a decrease in depression and mania, while there remained a 
significant decrease in mania when using an intent-to-treat analysis. 
Case studies have also been completed investigating the effect of EMP+ on bipolar 
disorder. Frazier and colleagues (2009) reported an outcome which was superior to 
conventional treatment after a 14 month intervention with EMP+ for a 12-year-old boy with 
early-onset bipolar I disorder mixed with psychotic features, GAD and OCD. Previous 
conventional treatments had resulted in intolerable side effects or inadequate treatment 
response. However, the participant was able to remain stable throughout a nine month follow-
up period on EMP+. Rucklidge and Harrison (2010) utilised an ABAB design with a one year 
follow-up in investigating the impact of EMP+ on the psychiatric symptoms of a 21-year-old 
female diagnosed with bipolar II disorder, ADHD, social anxiety and panic disorder. This 
participant demonstrated improvement while on EMP+, but remitted to baseline in terms of 




depression scores with a worsening in ADHD and anxiety symptoms when off EMP+. At one 
year follow-up the participant was in remission from all psychiatric disorders. 
Two case studies by Kaplan et al. (2002) have demonstrated the effect of EMP+ on 
mood, temper and explosive rage in two boys aged eight and 12 years. In both cases there 
was a significant effect on mood lability and temper control with a clear pattern of 
improvement while on the intervention and regression when the formula was withdrawn.  
Gately and Kaplan (2009) completed a database analysis of the effect of EMP+ on 
adults diagnosed with bipolar disorder, while Rucklidge, Gately and Kaplan (2010) 
completed a database analysis of the effect of EMP+ on children and adolescents diagnosed 
with bipolar disorder. Gately and Kaplan’s (2009) analysis found an overall 45% decrease in 
bipolar symptomology after 6 months on EMP+ in a total sample of 358 adults with bipolar 
disorder, while linear regression analysis over the first 6 months showed a decrease in 
medication. This medication reduction was also associated with an increase in the dosage of 
EMP+. Rucklidge et al. (2010) found a 46% drop in symptomology compared to baseline in 
their sample of 120 children and adolescents with bipolar disorder. This analysis also 
revealed that 46% of the sample had experienced an improvement which was greater than 
50% symptom reduction after 6 months on EMP+. The researchers also found no significant 
differences in results when comparing those children or adolescents diagnosed with bipolar 
disorder to those who also meet criteria for ADHD. 
An open-label case series of 11 children aged eight to 15 years completed by Kaplan, 
Fisher, Crawford, Field and Kolb (2004) investigated the effect of EMP+ on mood and 
behavioural problems. The children in the study had a range of disorders including bipolar, 
ADHD, ODD, Asperger’s, depression, anxiety, rage and Prader-Willi syndrome. Nine 
children completed the trial, with an average trial duration of 13.6 weeks. The researchers 




reported significant improvements in mood and anxiety for all who completed the trial, with 
effect sizes in the large range. 
The above studies support the use of EMP+ in the treatment of mood disorders in both 
children and adults. However, RCT studies are necessary to strengthen these claims and rule 
out placebo effects. 
 
1.7.2 EMP+ and Attention-Deficit/Hyperactivity Disorder, Autism Spectrum 
Disorder and other applications.  A study by Rucklidge, Taylor and Whitehead (2011) 
investigated the effect of EMP+ in a group of 14 adults with ADHD and severe mood 
dysregulation over an eight week open label trial with follow-up. The researchers found 
significant improvements on a number of measures, with moderate to large effect sizes. Of 
particular note was that mood and hyperactivity normalised. The above study by Kaplan and 
colleagues (2004) found a significant reduction in attention problems after intervention with 
EMP+ in their sample of 11 children which included five with a diagnosis of ADHD as well 
as mood problems. Similarly, the above mentioned case study by Rucklidge and Harrison 
(2010) found a significant improvement in ADHD symptomatology after intervention with 
EMP+. A recent double-blind, randomised, placebo-controlled trial by Rucklidge, Frampton, 
Gorman and Boggis (2014) found significant differences in self- and observer-rated measures 
of ADHD, favouring the micronutrient treatment group.  Furthermore, the clinicians rated 
those in the micronutrient group as more improved than those in the placebo group in terms 
ADHD symptoms and global functioning. There was also a larger improvement in mood for 
those who were moderately to severely depressed at baseline for the treatment group 
compared to placebo. This study, in light of the other studies completed, provides strong 
evidence for the potential of micronutrients in the treatment of ADHD, however further 




replication is necessary before micronutrients can be recommended to patients as another 
empirically supported treatment for their symptoms. 
Mehl-Madrona, Leung, Kennedy, Paul and Kaplan (2010) compared micronutrients to 
standard medication in the management of autism using a naturalistic case-controlled design. 
The researchers reported that both treatment groups saw significant improvement on the 
Childhood Autism Rating Scale and the Childhood Psychiatric Rating Scale. However, the 
micronutrient group experienced greater improvement than the medication group on the total 
Aberrant Behaviour Checklist scores. The micronutrient group had lower self-injurious 
behaviour intensity scores and greater improvement on the Clinical Global Impressions scale. 
While there were improvements in both groups, there were more advantages for the 
micronutrient treatment group than the medication treatment group. This suggests some 
potential of EMP+ in the management of behaviours associated with autism, although more 
research is necessary before EMP+ could become a recommended treatment. 
Other applications of EMP+ have also been investigated. For instance Harrison, 
Rucklidge and Blampied (2013) have proposed that EMP+ and micronutrient formulas like it 
may be useful in substance abuse following a case study by these researchers. The 
researchers found on-off control of psychiatric symptoms, as well as on-off use of cannabis 
and cigarettes during treatment with micronutrients for ADHD.  
Rodway, Vance, Watters, Lee, Bos and Kaplan (2012) investigated the efficacy of 
EMP+ in relation to childhood psychosis. They reported on a case study of an 11 year-old 
boy with a three year history of mental illness. After intervention with EMP+ the participant 
experienced complete remission of psychosis and a significant reduction in anxiety and 
obsessions. These gains remained present at a four-year follow-up. The authors concluded 
there is potential in the treatment of childhood psychosis with micronutrient formulas, 




especially in light of the fact that treatment with EMP+ cost only 1% of the participant’s 
inpatient mental healthcare (Rodway et al., 2012).  
As demonstrated, EMP+ has been widely researched for a number of different 
applications within the mental health field and shows potential for the treatment of a number 
of different disorders.  
 
1.8 Aims and Hypotheses 
The aim of the following study is to examine the effect of a broad-based micronutrient 
formula, EMP+, on anxiety in children. This research is completed as a pilot study to 
determine if the positive treatment effects of micronutrients on stress and anxiety in adults are 
also seen in a sample of children with elevated anxiety. The previous research on the effect of 
EMP+ on anxiety in children has been limited to case studies, often with participants whose 
other comorbid mental health disorders are the presenting problem. This research focuses on 
a group of children with significant anxiety as their primary difficulty and is the first study of 
EMP+ with such a focus to the best of the author’s knowledge.  
It is hypothesised that this study will find the following: 
1. The micronutrient formula will be associated with improvements in anxiety 
2. The micronutrient formula will be associated with improvements in overall 
functioning and in mood where mood is also elevated 
3. The micronutrient formula will not be associated with significant side-effects and that 
if present, side-effects will be minor and transitory 
4. Participants will be able to swallow eight pills per day and be compliant at doing so 










Participants were recruited in Canterbury, New Zealand, between August 2012 and 
September 2013 via referrals from general practitioners, clinical psychologists and online and 
paper advertising. From 36 referrals, 14 children aged between 8 and 11 years old, with 
significant difficulties with anxiety, participated in this study. Out of the 36 caregivers who 
completed the online screening questionnaire, 30 of their children met the required cut-off in 
terms of their child’s level of anxiety to allow them to participate (see inclusion criteria). 
Every person who reached the screening cut-off and all other eligibility criteria was contacted 
via email and offered an appointment to talk about potential participation.  
 One child was excluded because they were taking medication for anxiety and two 
more children were excluded because they lived outside of Canterbury. Two families who 
completed  online screening and attended the initial baseline appointment chose not to 
consent to the study; one withdrew due to family stress and the another due to the amount to 
travelling which would be involved given they lived rurally. All caregivers who chose not to 
participate were provided with a list of services and agencies that might be able to assist their 
child if they wished to seek treatment. One other family who meet online screening criteria 
was better suited for another study being completed within the research group.  
All study procedures were approved by both the Human Ethics Committee at the 
University of Canterbury and the Upper South A Regional Health and Disability Ethics 
Committee. The trial was registered prospectively with the Australian New Zealand Clinical 
Trials Registry (ACTRN12612000671864). 
 
2.1.1 Inclusion and exclusion criteria. In order to be considered for entry into the 
study, participants had to meet the clinical cut-off of 25 points on the Screen for Child 




Anxiety Related Disorders (Parent Version; SCARED). This score may indicate the presence 
of an anxiety disorder (Birmaher et al., 1999). Participants did not have to meet full criteria 
for an anxiety disorder, as identified in the DSM-IV. Also, participants were not excluded if 
they had a comorbid diagnosis, as non-exclusion would provide a more representative sample 
in terms of clients being treated in the community. Individuals were only considered if they 
were not taking psychiatric medications (or had been medication free for at least 4 weeks) 
Other inclusion criteria included: 
1) Participants had to be between 8-11 years of age. 
2) Each participant had to have a level of understanding sufficient to complete the 
questionnaires and examinations required by the protocol and be considered reliable 
and compliant with the protocol (including the ingestion of 8 capsules/day). 
3) Participants had to be able to eat at least a snack two times per day, so that the 
capsules would not be ingested on an empty stomach. 
4) Participants had to have a score of at least 50 (within the 41-50 point range, indicating 
a moderate degree of interference in functioning in most social areas or severe 
impairment of functioning in one area) on the Children’s Global Assessment Scale. 
 
Other exclusion criteria included: 
1) Any individual living outside of the Canterbury region. 
2) Any participant with a neurological disorder involving brain or other central function 
(e.g., epilepsy, MS, narcolepsy). Purely peripheral neurological problems were not 
excluded (e.g., Raynaud’s, peripheral diabetic neuropathy). 
3) Any participant with a serious medical condition for which major medical 
interventions were anticipated during the duration of the trial. 




4) Any participants known to be allergic to the ingredients of the intervention (including 
ginkgo biloba, germanium sesquioxide, or grape seed). 
5) Any participant with a known abnormality of mineral metabolism (e.g., Wilson’s 
disease, haemochromatosis). 
6) Participants were excluded temporarily if they have taken an oral antibiotic in the 
previous 6 weeks.  
7) Consumption of any type of nutritional or herbal supplement, known to have a 
centrally-acting effect, would result in a participant's exclusion. However, participants 
who had been taking supplements such as omega 3s or melatonin were permitted to 
enter the study if a) they had been taking these agents for at least one month prior to 
the study, and b) they continued on these agents throughout the study.  
8) Any participant judged clinically to be at serious risk for suicide or violence in the 
opinion of the researchers. 
These criteria resulted in three participants being excluded as noted above. Another 
participant was temporarily excluded after beginning a course of oral antibiotics. 
 
2.1.2 Final Sample. Eleven participants completed the entire trial. Current and past 
anxiety disorder diagnoses, as well as current supplement intake for each participant, are 
presented in Table 1. Ten out of 14 (71%) participants met a DSM-IV anxiety disorder 
diagnosis at the time of entry into the study based on the Kiddie Schedule for Affective 
Disorders and Schizophrenia for School-Age Children (Present and Lifetime version). As 
shown in Table 1, six participants (43%) had Separation Anxiety Disorder, four participants 
(29%) had Specific Phobia, six participants (43%) had Generalised Anxiety Disorder and one 
participant (7%) had Post-traumatic Stress Disorder. One participant also had a diagnosis of 
Attention Deficit Hyperactivity Disorder and another had a Specific Learning Disorder. Two 




participants had difficulties with sleep and had been taking melatonin prior to participation. 
All diagnoses were discussed with a senior clinical psychologist before being confirmed.  
One participant completed the baseline phase but chose to withdraw from the study 
prior to commencing the treatment phase due to illness in the family. Another participant 
failed to attend any appointments after week two of the intervention phase. Another 
participant withdrew after week six of the intervention phase due to parental separation. In 
addition, this participant had not taken the micronutrient since week four of the study, 
although they had not attended an appointment since week two of the intervention. Eleven 
out of fourteen of the final sample had sought some type of treatment prior to participating in 
the study, including herbal remedies and attending sessions with a mental health professional. 




Table 1: Current  Anxiety Diagnoses, Past Anxiety Diagnoses and Current Supplement Intake of the 
Final Sample of Participants 
Participant (age) Current Anxiety Diagnoses Past Anxiety Diagnoses Current supplements 







Participant 2 (8) Generalised Anxiety 
Disorder 
  




Fish oil, 300mg 
Participant 4 (8)    
Participant 5 (8) Generalised Anxiety 
Disorder 
  
Participant 6 (10) Generalised Anxiety 
Disorder 
   













Participant 9 (8) Separation Anxiety Disorder   




Participant 10 (8)    
Participant 11 
(10) 
Separation Anxiety Disorder 
Specific Phobia 




   
Participant 13 (8)    
Participant 14 (9) Separation Anxiety Disorder   
 
2.2 Measures 
2.2.1 Measurement of demographic variables. 
History Questionnaire. This questionnaire was used to assess demographic variables 
including the child’s ethnicity, parental marital status, parent occupation, household income, 
information about any previous or current contact with mental health professionals, any 
previous or current medication, family history of mental health disorders, antibiotic use 
history, allergies and other important relevant medical information.  
New Zealand Socioeconomic Index of Occupational Status. (NZSEI; Davis, McLeod, 
Ransom, and Ongley, 1997). The NZSEI is based on 1991 New Zealand Census data and 
provides an estimate of socioeconomic status (SES) based on an individual’s occupation. 
Scores range from 10 to 90 and higher scores indicate higher SES. 
 
2.2.2 Parent-rated dependent measures. 
Screen for Child Anxiety Related Disorders – parent version (SCARED). The 
SCARED (Birmaher et al., 1999) is a 41 item parent-rated measure of a broad range of 
anxiety symptoms in children. The SCARED assesses five factors of anxiety, namely panic 
disorder or significant somatic symptoms (e.g. “when my child feels frightened, it is hard for 
him/her to breathe”), generalised anxiety disorder (e.g. “My child worries about what is going 




to happen in the future”), separation anxiety (e.g. “My child doesn’t like to be away from 
his/her family”), social anxiety disorder (e.g. “It is hard for my child to talk with people 
he/she doesn’t know well”) and significant school avoidance (e.g. “My child is scared to go 
to school”). Answers are indicated on a 3-point Likert scale (“not true or hardly ever true” 
[0], “somewhat true or sometimes true” [1] and “very true or often true” [2]) and a score 
greater than 25 may indicate the presence of an anxiety disorder. Scores can range from 0 to 
81 points. The scale has an α-coefficient of 0.9 with a test-retest reliability of 0.86 and has 
been widely used in the community and in research. Furthermore, the total score is able to 
discriminate between children with anxiety disorders and those with non-anxiety disorders 
(Birmaher et al., 1999). 
Pediatric Emotional Distress Scale (PEDS). The PEDS (Saylor, Swenson, Reynolds, 
& Taylor, 1999) is a brief measure designed to detect elevated anxiety symptoms or 
behaviour in children following a traumatic event. The PEDS has three individual factors. 
These are acting out (e.g. “Wants things right away”), fearful (e.g. “Has trouble going to 
bed/falling asleep”) and anxious/withdrawn (e.g. “Seems sad and withdrawn”). Answers are 
given on a 4-point Likert scale (“almost never” [1], “sometimes” [2], “often” [3] or “very 
often” [4]), with a score of 28 or greater indicating clinically significant anxiety. Scores can 
range from 21 to 84 points. The scale has an alpha coefficient of 0.85 with moderate test-
retest reliability and inter-rater reliability, as well as evidence of convergent and discriminant 
validity (Saylor et al., 1999).  
Mood and Feelings Questionnaire – parent version (MFQ). The MFQ (Costello & 
Angold, 1988) is a parent rated measure of symptoms of depression in children. This 
questionnaire asks the parent how his/her child has been feeling and acting over the previous 
two weeks. The MFQ is rated on a 3-point Likert scale (“not true” [0], “sometimes” [1] and 
“true” [2]) and contains questions such as “s/he at more than usual” and “s/he cried a lot”. 




Scores can range from 0 to 68. The MFQ has been shown to reliably differentiate between 
depressed and non-depressed youth when using a clinically significant cut-off score of 27 and 
shows moderate to high criterion validity in both clinic and non-clinic settings (Kent, 
Vostanis, & Feehan, 1997; Daviss et al., 2006). The MFQ has high internal consistency with 
an α-coefficient of 0.96 and compares favourably with other measures of depression in 
children (Daviss et al., 2006). 
Strengths and Difficulties Questionnaire – parent version (SDQ). The SDQ 
(Goodman, 1997) is a brief measure of prosocial behaviour and psychopathology for 3-16 
year olds. It asks about a range of positive and negative attributes, rated on a 3-point Likert 
scale (“not true” [0], “somewhat true” [1] and “certainly true” [2]) to produce scores on 5 
scales; emotional symptoms (e.g. “many worries, often seems worried”), conduct problems 
(e.g. “often lies or cheats”), hyperactivity/inattention (e.g. “constantly fidgeting or 
squirming”), peer relationship problems (e.g. “rather solitary, tends to play alone”) and 
prosocial behaviour (e.g. “helpful if someone is hurt, upset or feeling ill”). A clinically 
significant cut-off of 17 is used to indicate abnormally elevated scores for total difficulties, 
with a range from 0 to 40. The SDQ compares well to other valid and reliable behavioural 
screening questionnaires (Goodman, 1997). The parent version of the SDQ demonstrates 
reasonable correlations with the child-rated version and has a Cronbach’s α of 0.82 and a test-
retest reliability over four to six months for the total scale of 0.72 (Goodman, 2001). 
Furthermore, scores above the 90th percentile predict a significantly increased probability of 
having a psychiatric disorder (Goodman, 2001). 
 
2.2.3 Child-rated dependent measures. 
Revised Children’s Manifest Anxiety Scale (RCMAS). The RCMAS, also titled “What 
I Think and Feel” (Reynolds & Richmond, 1978) is a self-report measure assessing anxiety 




in children. Each item is rated as “Yes” (1 point) or “No” (0 points) depending on whether 
the child thinks that item is true about them. The RCMAS produces three scales; 
physiological anxiety (e.g. “It is hard for me to get to sleep at night”), worry/oversensitivity 
(e.g. “I worry about what is going to happen”) and social concerns/concentration (e.g. 
“Others seem to do things easier than I can”), as well as a social desirability scale. A 
clinically significant cut-off of 19 out of 28 is recommended (Stallard, Velleman, Langsford 
& Baldwin, 2001). The reliability coefficient for the RCMAS scale is 0.83 and the measure 
demonstrates good construct and convergent validity (Reynolds, 1982; Reynolds & 
Richmond, 1979). 
Measure Yourself Medical Outcome Profile (MYMOP). The MYMOP (Paterson, 
1996) is a self-report outcome questionnaire asking about the symptoms and side-effects 
which the patient considers the most important, allowing for measurement of change. While 
some symptoms were assigned to all participants in this study, the scale allows for 
participants to choose some of the symptoms they would like to measure based on their own 
view of the symptoms importance and impact on themselves. The item is rated on a 5-point 
Likert scale from “major problem this week” (4 points) to “excellent – zero problems” (0 
points). This questionnaire shows construct and criterion validity as well as sensitivity to 
change when compared to another medical outcome measure. 
 
2.2.4 Clinician-rated dependent measures. 
Clinical Global Impressions Scale (CGI). The CGI (Guy, 1976; Spearing, Post, 
Leverich, Brandt & Nolen, 1997) is a three-item rating of the clinician’s assessment of 
symptoms in relation to the clinician’s total experience with a patient. Its goal is to allow the 
clinician to rate the effectiveness of treatment, change over time and the severity of illness. 
Scales range from “normal, not ill” (1 point) to “very severely ill” (7 points) or from “very 




much improved/markedly improved” (1 point) to “very much worse/markedly worse” (7 
points) over a 7-point scale. Up to three different dimensions can be rated, such as anxiety or 
depression (Spearing et al., 1997). The CGI is one of the most widely used outcome measures 
for psychological research and has high interrater reliability (Spearing et al., 1997). 
Children’s Global Assessment Scale (CGAS). The CGAS (Shaffer et al., 1983) is a 
global measure of social and psychiatric functioning in children. The CGAS is a single 
numerical scale from 1 (lowest functioning) through 100 (high functioning) that is separated 
into 10-point anchors with descriptors of functioning and psychopathology to guide scoring. 
The CGAS is based on the Global Assessment of Functioning measure for adults and can be 
used to track change over time. High reliability is usually found in clinical research (Storch, 
2005) and test-retest reliability has been found to be around 0.85 (Rush, First & Blacker, 
2008). 
Child Depression Rating Scale (CDRS). The CDRS (Poznanski, Cook & Carroll, 
1979) is a 16-item measure, used for children aged 6-12 years old, to assess the severity of 
depression. Assessment information is based on interviews with the child and parent and the 
scale was designed to be used in the same way as the Hamilton Depression Rating Scale. 
Items provide descriptive information for every point given on each individual item. Items 
are scored from 0 to 2, 3, 4 or 5 points depending on the item. Scores range from 16 to 63, 
with those above 30 indicating clinically significant elevation in symptoms (Shanahan, 
Zolkowski-Wynne, Coury, Collins & O’Shea, 1987). The CDRS offers an effective way to 
monitor treatment response and appears to be a valid measure of depression in children 
(Shanahan et al., 1987).  
Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children-
Present and Lifetime version (K-SADS-PL). The K-SADS-PL (Kaufman et al., 1997) is a 
semi-structured diagnostic interview that assesses current and lifetime history of psychiatric 




disorders in children and adolescents in alignment with DSM-III-R and DSM-IV criteria. The 
interview is administered by a trained clinician. For this study, only the anxiety disorders 
sections (Screen Interview questions and Anxiety Disorder Supplement if necessary) were 
administered. Diagnoses are made through synthesising of parent and child responses. The K-
SADS-PL has been widely used in research and has high interrater reliability (98%) and good 
test-retest reliability for any anxiety disorder (κ=.80 for 1-5 weeks; Kaufman et al., 1997). 
 
2.3 Design and Procedures 
Participants first completed the screening process then eligible participants were 
invited to participate in the study. Next participants completed a baseline period. The study 
followed a multiple baseline/multiple probe design (Cooper, Heron, & Heward, 2007), where 
participants were randomly assigned to a baseline period of one, two or three weeks in length 
and thereafter entered a treatment phase.  The baseline and intervention phases had the 
character of a multiple probe design (Cooper, et al., 2007, pp 209-211), with probes in which 
dependent variables were gathered only at the beginning and the end of the assigned baseline 
period, such that all participants had two probes in baseline and four in the treatment phase. 
Probes, rather than daily or weekly measures, were used in this way to reduce the already 
large assessment burden on the child and her/his family.  Subsequent to the baseline phase, 
participants completed an eight week intervention phase were they took micronutrients and 
visited the University of Canterbury for monitoring every two weeks. The final phase of the 
study was a follow-up appointment three months after the participant finished the 
intervention phase. All participants were monitored by a clinical psychology graduate student 
under a clinical psychologist’s supervision. 
 




2.3.1 Screening phase. Caregivers who were interested in the study completed the 
online screening questionnaire, which could be accessed via the Mental Health and Nutrition 
Research Group’s website, www.mentalhealthandnutrition.co.nz. The screening 
questionnaire is displayed in Appendix B. It required contact information and answers to 
eligibility criteria, followed by completion of the SCARED. Applicants who met exclusion 
criteria were provided with a statement explaining why they were ineligible for the study, 
providing the researcher’s contact details and thanked for their time. At the end of the 
questionnaire, the caregiver was given an opportunity to make any comments, after which 
they were thanked for completing the questionnaire, informed that the researcher would 
contact them about their child’s eligibility to participate as soon as possible and provided 
with the researcher’s contact details. 
Applicants who met the study criteria were emailed and asked if they and their child 
would like to make an appointment to meet with the researcher at the University of 
Canterbury to discuss the study and participation.  
During this initial appointment the participant was provided with an age appropriate 
information sheet and the caregiver was given a more detailed information sheet. See 
Appendix C for the information sheets, consent and assent forms. The study was explained to 
the participant and his/her caregiver, including the aims and purpose of the study, what would 
be required of the participant and his/her caregiver and the risks. Each family was given a 
chance to ask questions of the researcher about the study. Families were informed of other 
treatments available in the community and participants were not encouraged to come off 
conventional treatment which was working in order to participant in this trial. In addition, the 
researcher enquired about the nature of the child’s difficulties in more detail than garnered 
through the screening questionnaire. Each family was provided with multiple opportunities to 
ask questions and participants were informed that they could withdraw from the study at any 




time. Families were given time to talk without the researcher present and provided with the 
option to take time to consider participation and to contact the researcher at a later date prior 
to consenting. Informed consent was obtained from the caregiver and assent from the child. 
 
2.3.2 Baseline phase. After a participant consented, he/she was assigned a participant 
identification number. Numbers were given in consecutive order, from one to 14. The 
participant was also informed of his/her baseline length. Baseline lengths were randomly 
assigned to identification numbers and the researcher was blinded to these. The caregiver 
completed the following questionnaires: SCARED, PEDS, MFQ, and History Questionnaire. 
The participant was assisted to complete the RCMAS and MYMOP. Once the caregiver and 
participant had completed all measures the researcher completed the CGI, CGAS and CDRS 
with the family. The participant was then provided with information on pill swallowing in the 
form of a video, a small box of candy to practice swallowing with and a pill-swallowing diary 
to complete over the baseline period. At each visit the caregiver was given a $10 petrol 
voucher as compensation for travelling to attend the appointment.  
One, two or three weeks following the initial baseline appointment, as determined by 
the random assignment to baseline length, the participant and caregiver returned for the final 
baseline appointment. At this appointment the caregiver completed the SCARED, PEDS, 
MFQ and SDQ, the participant completed the RCMAS and MYMOP and the clinician 
completed the CGI, CGAS and CDRS, as well as the Anxiety Disorder section of the K-
SADS-PL. Then participants were given one bottle of EMP+, enough for four weeks, with 
instructions on how to take the micronutrient and titrating the dosage over the next four days. 
The caregiver was instructed to contact the researcher if the child experienced any adverse 
effects from the micronutrient.  




Intervention, titration and dosage. EMPowerplus (EMP+) is a broad-spectrum 
micronutrient formula which contains 16 trace minerals, 14 vitamins, 3 amino acids and 3 
antioxidants. An ingredient list of EMP+ is included in Appendix A. The development and 
history of EMP+ was discussed in the Introduction above. Participants titrated up their dose 
over four days to eight capsules per day, in two doses of four capsules, taken with food and 
water. Participants were provided with EMP+ at no cost for the duration of the study and 
provided with another bottle if they decided to continue with the intervention during the 
follow-up period. Some participants struggled to swallow the recommended quantity of 
capsules so took the equivalent dosage in power form. For some participants the 
recommended daily dose caused side effects, thus the dose was divided into three doses or the 
dosage decreased then increased slowly over the following two weeks, if the participant 
remained side effect free. Emphasis was placed on the importance of taking EMP+ with 
plenty of food and water. Instructions for taking EMP+ are given in Appendix D. 
 
2.3.3 Intervention phase. Participants and families were seen at two weeks, four 
weeks and six weeks post final baseline. At these appointments the participants’ physical and 
mental health was reviewed and the following measures were completed: SCARED, PEDS, 
MFQ, RCMAS, MYMOP, CDRS, CGI and CGAS. A side effect questionnaire was 
completed at every appointment (see Appendix E). This questionnaire covered typical side 
effects of medications, such as dry mouth, headaches and nausea. A protocol for serious 
adverse events had been established, including stopping rules and discontinuation criteria, 
although this protocol was not utilised at any time throughout the study. Any issues with 
taking EMP+ were addressed and side effects monitored and remedied as necessary by 
reducing the dosage and adjusting diet.  




At eight weeks post final baseline participants finished the trial. At this appointment, 
the participants’ physical and mental health was reviewed and the following measures were 
completed: SCARED, PEDS, MFQ, SDQ, RCMAS, MYMOP, CDRS, CGI and CGAS. The 
participant and caregiver were asked how they felt the study had gone, if there were any 
changes they had noticed, any feedback for the researcher and whether they planned to 
continue taking EMP+. If the participant intended to remain on the micronutrient they were 
given another bottle of EMP+ or a similar micronutrient (a newer version of EMP+ with 
similar ingredients). They were also provided with contact details for the supplier of EMP+ if 
they wished to purchase it in the future. The participant and caregiver were thanked for 
participating in the study, and informed that the researcher would be in contact in 
approximately three months’ time to follow-up on the participant’s mental health and 
functioning. 
 
2.3.4 Follow-up phase. Approximately three months after the end of the intervention 
phase families were contacted to attend a follow-up appointment. At this appointment the 
participants’ physical and mental health was reviewed and the following measures were 
completed: SCARED, PEDS, MFQ, SDQ, RCMAS, MYMOP, CDRS, CGI and CGAS. The 
participant and caregiver were asked about the child’s current experiences with anxiety, 
whether they continued to take the micronutrient and why they did or did not continue. 
 
2.4 Statistical Analyses 
The primary outcome measures were the SCARED, PEDS and CGAS. The SCARED 
reflects a broad spectrum of anxiety symptoms, while the PEDS assesses primarily anxiety 
symptoms associated with experiencing trauma given this study was conducted in a region 
recently affected by large earthquakes. The CGAS provided a measure of overall functioning. 




Individual changes over experimental phases are analysed using modified Brinley plots 
(Blampied, 2007, 2014; Jacobson, Follette, & Revenstorf, 1984; Sobell, Sobell, & Gavin, 
1995), shown for the primary outcome measures (SCARED, PEDS and CGAS) and then for 
the secondary outcome measures (RCMAS, MYMOP, MFQ, CDRS and SDQ). Group mean 
comparisons were made between baseline phases, between baseline and treatment phases, 
and between end of trial and three-month follow-up for the same set of variables. Group 
mean comparisons were conducted using paired sample t-tests, with p-values given for t-tests, 
as well as Cohen’s d effect sizes. Changes between time points are illustrated by mean 




The results of the intervention as assessed by the primary and secondary outcome 
measures are presented in the following sections. Individual changes over experimental 
phases analysed using modified Brinley plots (Blampied, 2007, 2014; Jacobson et al., 1984; 
Sobell et al., 1995) are shown first. Tables showing group mean comparisons between 
baseline phases (Table 4), then between baseline and treatment phases (Table 5), and lastly 
between end of trial and three-month follow-up (Table 6) are then displayed. Demographic 



























Note. Estimated household SES was calculated as the mean household score on the New Zealand 
Socioeconomic Index of Occupational Status were scores range from 10 to 90 whereby higher scores indicate 
higher SES (see method for more information).  
 
3.1 Safety and Adherence 
Adverse effects experienced by participants in the study were mild to moderate 
intensity (one participant experienced moderate level side effects) and able to be remedied by 
reducing dosage or with diet modification (e.g. taking the micronutrient with more food and 
water). This was true of all but one participant, who continued to experience mild nausea for 
approximately thirty minutes after taking the recommended morning dose throughout the 
trial. 
 Five out of fourteen (36%) participants experienced side effects which may have 
been related to the intervention. Two participants experienced nausea and three experienced 
gastrointestinal disturbances which were definitely related to the intervention. Another 
participant experienced gastrointestinal symptoms which may have been related to the 
Table 2: Demographic Characteristics of Final Sample 
Characteristic Number Mean Standard 
deviation 
Percentage 
Sex     
Male 7   50 
Female 7   50 
Age in years (mean)  9.4 1.1  
Estimated household SES   94.7 42.1  
Ethnic group     
NZ European/Pakeha 11   79 
Maori 2   14 
Other 1   7 




intervention. Three participants experienced agitation on the pills. This occurred in the first 
two weeks of the intervention. Reducing the dosage then slowly increasing over the next 
three to four weeks remedied this symptom, which was probably related to the intervention, 
given the number of participants who experienced agitation and its proximity to the 
beginning the intervention. Dry mouth, sleep disturbance and nose bleeds were also 
experienced at some point in the trial by a participant. These results are presented in Table 3. 
Nine (64%) of the participants were compliant in terms of adherence to the treatment 
protocol. These participants were those who took the micronutrients at the recommended 
dose and did not miss a significant number of doses during the trial, which was defined as a 
compliance rate greater than 80%. Of the nine compliant participants, three (33%) took the 
micronutrients at a lower dose than eight pills per day (from four to six pills per day). This 
was either because they could not manage the number of pills which needed to be taken or 
experienced side effects at the recommended dose and thus stayed at a lower dose with fewer 
side effects. These participants are referred to as compliant – low dose in the following 
sections.  
Non-compliant participants were those who achieved a compliance rate of less than 
80%. This was either through forgetting to take a number of doses or having spent the 
majority of the trial going on and off the micronutrient for various reasons such as illness, 
taste of the powder and lack of effect (and so low motivation to be compliant). Furthermore, 
two participants opted to take the powder form of EMP+: one after trialling the pills and 
finding the quantity too difficult to take, while another participant refused to try the pills. One 
of these participants took the powder at a lower dose but was compliant, and the other 
participant was non-compliant. Another two participants opted to try the powder after some 
time on the pills, but found it more convenient to take the pills and so switched back to the 
capsule form. 




Table 3: Treatment-emergent adverse effects reported by at least 5% of 
participants during the trial 
 Definitely related  Possibly related 
Adverse effect n %  n % 
Gastrointestinal disturbance 3 21  1 14 
 Nausea 2 14    
Agitation    3 21 
Headache    1 7 
Dry mouth    1 7 
Sleep disruption    1 7 
Nose bleed    1 7 
 
3.2 Brinley Plot Analyses 
Data are presented below visually using modified Brinley plots (Blampied, 2007, 
2014; Jacobson, et al., 1984; Sobell et al., 1995).  Brinley (1965) introduced these plots as a 
way of presenting group mean data from cognitive psychology experiments. Mean group 
values were displayed as a scatter-plot, in such a way as to compare results within many 
conditions of the experiment with data in each condition categorised dichotomously, e.g., 
mean reaction times of men versus mean reaction times of women. If there was no systematic 
effect of the categorical variable (e.g., if male reaction times were the same as female 
reaction times) the condition data points lie on the diagonal (so long as the X and Y 
coordinates have the same origin and scale). If, however, the categorical variable did have a 
systematic effect, data points deviate from the diagonal. For a recent example see Dye, 
Green, and Bavelier (2009), who used Brinley plots to show that over many conditions and 




experiments, experienced video-game players have systematically faster reaction times than 
novice video-game players.   
In the case of modified Brinley plots, data from individuals rather than group means is 
plotted (Blampied, 2007; 2014; Rucklidge & Blampied, 2011). For each individual, a 
measurement made at Time 1 (T1) is plotted on the X axis against a measurement on the same 
variable, for the same individual, at some subsequent time (Tx), which is plotted on the Y 
axis. If there has been no change in the measure between T1 and Tx the data point will lie on 
the diagonal line, the line of no effect (or close to it if there has been measurement error 
without any intrinsic change in the variable measured). If, however, there has been change 
over time, the data point will lie somewhere off the line. If data from many individuals are 
thus plotted, systematic effects over time will be shown by systematic deviations from the 
diagonal line. To assist interpretation, lines showing clinically significant cut-off scores for 
the particular measure (Jacobson, et al, 1984) can be drawn (vertically to show the cut-off at 
T1, horizontally to show it for Tx) and the mean, confidence interval, and other measures of 
variance can also be shown. Capstick and Blampied (2004) and Blampied (2007) have 
proposed that Brinley plots are particularly useful and relevant for single-case research as 
they show the effect of an intervention, yet also preserve each individual’s identity in the 
visual display.  
Data for the study are presented as scores on a measure at one particular time-point 
plotted against scores on that same measure at another particular time-point. As described 
above, an effect is observed when scores deviate from the line of no effect. For the SCARED, 
PEDS, RCMAS, MYMOP, MFQ, CDRS and SDQ, points which fall below the line reflect a 
decrease in score and thus improvement, while those that fall above the line, show an 
increase in score and so some deterioration. However, on the CGAS the opposite is true, such 




that points which fall above the line reflect an increase in score and thus an improvement in 
functioning. Points which fall below the line indicate a decline in functioning on the CGAS.  
With clinical cut-off lines added, and when reduced scores indicate improvement, 
scores which fall below the line of no effect and below the horizontal clinical cut-off line 
indicate improvement and a non-clinical score at T2. In addition, scores which fall below the 
line of no effect and horizontal line as well as to the right of the vertical cut-off line show that 
the individual scored in the clinically significant range at the earlier time-point but was in the 
non-clinical range at the latter time-point. 
Arrows are also displayed on the graphs and show the directional change which 
would be indicative of improvement. In addition, the crosses shown on each graph represent 
the mean and confidence intervals for each time-point. The point where the lines that form 
the cross intersect show the means for each time-point presented on each axis. The lengths of 
the lines themselves show the 95% confidence interval for each mean. This confidence 
interval represents the range in which we can expect the true mean to fall 95% of the time, if 
the trial was repeated multiple times. Thus, if the mean and confidence interval fall below the 
line of no effect we can infer that there is likely some effect of the intervention, as the mean 
is clearly different from the point prediction of the T2 mean being equal to the T1 mean. This 
is true of all measures, except the CGAS where the opposite would be true such that if the 
mean and confidence interval are above the line of no effect we can infer that there is likely 
some effect of the intervention, and that the post-treatment mean is different from the point 
prediction of no effect. Refer to Figure 1 below for an interpretation of modified Brinley 
plots. 
The following figures show the same series of eight Brinley plots presenting the same 
comparisons for each of the main measures within the trial. These are: Baseline 1 (X axis) 
versus Baseline 2 (Y axis), Baseline 2 (X axis) versus Week 2 (Y axis), Baseline 2 (X axis) 




versus Week 4 (Y axis), Baseline 2 (X axis) versus Week 6 (Y axis), Baseline 2 (X axis) 
versus End of Trial (Y axis), Baseline 2 (X axis) versus Follow-up (Y axis) and End of Trial 
(X axis) versus Follow-up (Y axis). The eighth plot compares Baseline 2 (X axis) versus End 
of Trial (Y axis) using an intent-to-treat analysis, such that for participants who did not 
complete the trial, their last data point was carried forward and used as the end of trial score, 
making for a more conservative comparison. Note also that Baseline 2 data were used as the 
primary baseline data, as opposed to Baseline 1 or an average of both sets of baseline data, 
given that it was common to see a trend toward a decrease in symptom severity over the 
baseline period. However, as demonstrated in Table 3, there was a statistically significant 
decrease over the baseline phase for only two measures, the SCARED and PEDS. Thus 
Baseline 2 was used as the primary baseline data as this also provides, along with using the 
intent-to-treat method, a more conservative measure to compare the intervention to. 
In addition, this final plot also displays data separated by compliance level and the 
first plot (Baseline 1 [X axis] versus Baseline 2 [Y axis]) is split such that the baseline length 
is shown for each participant. This allows for any trends related to the length of baseline to be 
seen. In that first plot Group 1 refers to participants with a one week long baseline period, 
Group 2 refers to participants with a two week long baseline period and Group 3 refers to 
participants with a three week long baseline period. 
The average increase or decrease in scores from Baseline 2 to End of Trial for each 
measure was calculated by determining the percentage change for each participant using the 
full sample of 14 participants and the intent-to-treat method detailed above, then calculating 
the mean of these percentage changes. 






















































Figure 1. Modified Brinley plot interpretation (after Rucklidge & Blampied, 2011). Note that 
this interpretation applies where improvement is signalled by a reduction in score, indicated 
by the arrow to the right of the Y axis.   
 
3.2.1 Primary measures. Figure 2 shows the effect of micronutrient intervention on 
the primary measure of anxiety, the parent-rated Screen for Child Anxiety Related Disorders 
(SCARED). The initial plot presenting Baseline 1 versus Baseline 2 shows a trend toward a 
decrease in anxiety level over the baseline period. It also shows that the majority of 
participants, nine out of 14 (64%), were over the clinical cut-off in terms of anxiety during 
the entire baseline period. Over the course of the next four plots, a steady decrease in scores 
is seen, until by the end of the trial, 10 of the 11 (91%) participants who completed the trial 
fall below the clinical cut-off in terms of anxiety level, including six out of seven (86%) of 
completers who were over the clinical cut-off at Baseline 2 and fell below the clinical cut-off 
at End of Trial. Furthermore, the mean and confidence interval for End of Trial was below 




the clinical cut-off line and line of no effect. The Baseline 2 and End of Trial scores gave an 
average decrease in anxiety level of 58%. These gains continue to be seen at follow-up. 
However, there is little or no change seen in anxiety level from End of Trial to Follow-up as 
demonstrated on the plot comparing these time points.  
The final plot presenting Baseline 2 versus End of Trial shows that overall, non-
compliant participants demonstrate little change in anxiety during the course of the 
intervention as demonstrated by the means and confidence intervals for this group. This is in 
stark comparison to compliant and compliant – low dose participants who all showed 
improvement and fell below clinical cut-off following the micronutrient intervention, as seen 
by the individual data points and the means and confidence intervals for these groups. 













Figure 2. Modified Brinley plots showing the effect of micronutrient intervention on anxiety 
as measured by the SCARED. 
 
Figure 3 shows the effect of micronutrient intervention on the parent-rated Pediatric 
Emotional Distress Scale (PEDS).  The initial plot presenting Baseline 1 versus Baseline 2 
shows a trend toward a decrease in anxiety level over the baseline period, as demonstrated by 
the means and confidence intervals for these time-points. It also shows that all participants 
were over the clinical cut-off in terms of anxiety during the baseline period.  
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Over the course of the next four plots a decrease in scores is seen, until by the end of 
the trial five out of 11 (46%) of participants who completed the trial fall below the clinical 
cut-off in terms of anxiety level. The mean for the End of Trial lies about the clinical cut-off 
line, although the lower bound of the confidence interval for this mean is below the clinical 
cut-off line. The Baseline 2 and End of Trial scores gave an average decrease in anxiety level 
of 25%. The gains made at End of Trial continue to be seen at Follow-up, with the mean 
falling below the clinical cut-off at follow-up. However, there is only a small further decrease 
in anxiety level seen from End of Trial to Follow-up as demonstrated on the plot comparing 
these time points.  
The final plot presenting Baseline 2 versus End of Trial shows that overall, compliant 
and non-compliant participants demonstrated a similar level of change in anxiety over the 
course of the intervention, as illustrated by the means and confidence intervals for the two 
different compliance groups.  However, compliant participants started and finished the study 
at a lower level of anxiety, with the mean falling below the clinical cut-off, although the 
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Figure 3. Modified Brinley plots showing the effect of micronutrient intervention on anxiety 
as measured by the PEDS.  
Note. The possible range of scores for the PEDS is 21 to 84. 
 
Figure 4 shows the effect of micronutrient intervention on the Children’s Global 
Assessment Scale (CGAS), a clinician-rated measure of functioning. The initial plot 
presenting Baseline 1 versus Baseline 2 illustrates that level of functioning remained 




consistent over the baseline period. Over the following four plots a steady increase in scores 
is seen, indicating improvement in functioning, such that by the end of the trial 10 out of 11 
(91%) participants had moved above the line of no effect. The Baseline 2 and End of Trial 
scores gave an average increase in functioning of 18%.  The plot presenting End of Trial 
versus Follow-up demonstrates that participants whose follow-up data were collected, tended 
to continue to improve, as shown by the mean and confidence interval for Follow-up, 
although the lower bound of the confidence interval overlapped the line of no effect and some 
data points fell below the line.   
The final plot presenting Baseline 2 versus End of Trial shows that overall, non-
compliant participants demonstrate a small, if any, increase in functioning over the course of 
the intervention, as shown by the means and confidence intervals for this group. In 
comparison, the compliant and compliant – low dose participants improved more than the 
non-compliant group, as seen by the individual data points and the means and confidence 
intervals for these groups. Of note is that the mean and confidence intervals for the compliant 
group fall above the line of no effect, although it is also noted that this group was slightly 















Figure 4. Modified Brinley plots showing the effect of micronutrient intervention on 
functioning as measured by the CGAS. 
Note. The range of scores for the CGAS is 0 to 100. 
 
3.2.2 Secondary measures. Figure 5 shows the effect of micronutrient intervention 
on the child-rated Revised Children’s Manifest Anxiety Scale (RCMAS). The initial plot 
presenting Baseline 1 versus Baseline 2 shows a large scatter among the individual data 
points around the line of no effect, indicating a large range of change in the baseline period, 
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with some participants improving and some participants worsening in terms of anxiety. While 
it appears that four out of five (80%) participants in Group 1 (one week baseline period) saw 
an increase in anxiety over the baseline period, the overall means and confidence intervals 
show there was little to no change in anxiety over the baseline period for this measure. It also 
shows that three out of 14 (21%) participants were over the clinical cut-off at the end of the 
baseline period and two out of 14 (14%) throughout the entire baseline period.  
Over the course of the next four plots there is a general trend toward a decrease in 
anxiety. By the end of the trial nine out of 11 (82%) participants who completed the trial fell 
below the clinical cut-off in terms of anxiety level, including two out of the three (67%) 
completers who were over the clinical cut-off at Baseline 2. Also, the mean and confidence 
interval for the end of the trial fell below the line of no effect, indicating significant 
improvement. The Baseline 2 and End of Trial scores gave an average decrease in anxiety 
level of 43%.   
These gains continue to be seen at Follow-up; however, there is little or no change 
seen in anxiety level from End of Trial to Follow-up as demonstrated on the plot comparing 
these time points. The final plot presenting Baseline 2 versus End of Trial shows that overall, 
both non-compliant and compliant groups decreased in anxiety throughout the intervention. 
However, the compliant group decreased more than the non-compliant group despite having 












Figure 5. Modified Brinley plots showing the effect of micronutrient intervention on anxiety 
as measured by the RCMAS. 
 
Figure 6 shows the effect of micronutrient intervention on the Measure Yourself 
Medical Outcome Profile (MYMOP), a child-rated measure of anxiety symptoms. The initial 
plot presenting Baseline 1 versus Baseline 2 shows a trend toward a small decrease in anxiety 
symptoms over the baseline period. However, the confidence intervals for the mean do 
overlap with the line of no effect and the individual data points show a range of scatter above 
Baseline 2




















































































































Compliant - low dose 
Non-compliant
Compliant and low dose
Non-compliant




and below this line. Over the course of the next four plots, the means and confidence intervals 
for the intervention phase time-points drop below the line of no effect, until by the end of the 
trial seven out of 11 (64%) participants who completed the trial fall below the line of no 
effect. The Baseline 2 and End of Trial scores gave an average decrease in anxiety level of 
34%. These gains continue to be seen at Follow-up, although there is a further small decrease 
in anxiety symptoms as indicated by the means on the plot comparing End of Trial to Follow-
up. However, the confidence intervals do overlap with the line of no effect and there is also 
some scatter either side of this line. 
The final plot presenting Baseline 2 versus End of Trial shows that overall, non-
compliant participants demonstrate little change in anxiety over the course of the 
intervention, as illustrated by the means and confidence intervals for this group. In 
comparison, the means and confidence intervals for the compliant and compliant – low dose 
group fell below the line of no effect, with six out of nine (67%) participants from the 
compliant groups also falling below this line. However, the non-compliant group also began 















Figure 6. Modified Brinley plot’s showing the effect of micronutrient intervention on anxiety 
as measured by the MYMOP.	   
 
Figure 7 shows the effect of micronutrient intervention on the Mood and Feelings 
Questionnaire (MFQ), a parent-rated measure of mood. The initial plot presenting Baseline 1 
versus Baseline 2 shows an overall trend toward little change in mood over the baseline 
period, with a range of scatter above and below the line of no effect, and the means falling 
very near this line. It also shows that three out of 14 (21%) participants were over the clinical 
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cut-off in terms of mood during the entire baseline period and four out of 14 (29%) by the 
end of the baseline period. Over the course of the next four plots there is a decrease in scores 
until by the end of the trial, all participants fall below the clinical cut-off in terms of mood, 
with 10 out of 11 (91%) participants who completed the trial falling below the line of no 
effect. The Baseline 2 and End of Trial scores gave an average decrease in mood of 54%. 
These gains continue to be seen at follow-up. However, there was no change seen in mood 
from End of Trial to Follow-up as demonstrated on the plot comparing these time points.  
The final plot presenting Baseline 2 versus End of Trial shows that overall, compliant 
and compliant – low dose participants tended to improve and remain under the clinical cut-off 
by the end of the trial, while non-compliant participants moved from being over the clinical 
cut-off to under it, as seen by the means for the two groups. However, the confidence 
intervals for the non-compliant group did overlap the clinical cut-off lines and line of no 
effect. This final plot also demonstrates a similar degree of improvement among both the 
compliant and non-compliant groups, though the non-compliant group had more 
symptomatology at Baseline 2 and remained more symptomatic than the compliant group at 















Figure 7. Modified Brinley plots showing the effect of micronutrient intervention on anxiety 
as measured by the MFQ. 
 
Figure 8 shows the effect of micronutrient intervention on the Children’s Depression 
Rating Scale (CDRS), a clinician-rated measure of mood. The initial plot presenting Baseline 
1 versus Baseline 2 shows a trend toward a small decrease in mood over the baseline period, 
as demonstrated by the mean and confidence intervals for this plot. It also shows that by 
Baseline 2, all participants were under the clinical cut-off in terms of mood symptoms. Over 
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the next four plots a decrease in scores is seen until by the end of the trial the mean and 
confidence intervals are very close to the minimum possible score (16) and all participants 
remain under the clinical cut-off.  The Baseline 2 and End of Trial scores gave an average 
decrease in mood symptomatology of 13%. These gains continue to be seen at Follow-up, 
although there is little or no change seen in mood symptoms from End of Trial to Follow-up 
as demonstrated on the plot comparing these time points.  
The final plot presenting Baseline 2 versus End of Trial shows that overall, the non-
compliant group remained more symptomatic in terms of mood symptoms than compliant 
participants; however, the non-compliant group began the trial with a higher mean score. 
Despite this, both groups were under the clinical cut-off at End of Trial. This is demonstrated 
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Figure 8. Modified Brinley plots showing the effect of micronutrient intervention on anxiety 
as measured by the CDRS. 
Note. The range of scores for this measure is 16 to 62 
 
Figure 9 shows the effect of micronutrient intervention on the parent-rated Strengths 
and Difficulties Questionnaire, a measure of functioning difficulties in daily life. Because this 
measure was only completed at the beginning and end of the intervention phase and follow-




up, there are only four Brinley plot comparisons made. In addition, data was missing for two 
participants, resulting in a sample of nine participants who completed the trial. The initial plot 
presenting Baseline 2 versus End of Trial shows a trend toward a decrease in total difficulties 
a child has with everyday life, as shown by the mean and confidence interval for End of Trial. 
By the end of the trial, all participants who completed the trial fell under the clinical cut-off, 
with seven out of nine (78%) participants seeing some decrease in total difficulties. These 
gains are maintained at Follow-up. However, there was no change from End of Trial to 
Follow-up as demonstrated on the plot showing these time points. Of note is that one 
participant was above the clinical cut-off at Follow-up, having previously been below the 
clinical cut-off at the end of the trial, despite continuing to take a micronutrient compound 
(Daily Essential Nutrients, a newer version of EMP+ with very similar ingredients), albeit at 
a lower dose than in the trial. This converts to 17% of participants at Follow-up worsening 
between End of Trial and Follow-up. 
The final plot presenting Baseline 2 versus End of Trial showed that the overall, non-
compliant participants demonstrated little or no change in level of difficulties with everyday 
life over the course of the intervention, as illustrated by the means and confidence intervals 
for this group. In addition, the mean for this group at Baseline 2 and End of Trial is above the 
clinical cut-off throughout the trial. This is in comparison to the compliant groups, who 
experienced a decrease in level of everyday difficulties, such that all participants fell below 
the clinical cut-off following the micronutrient intervention, including the two participants 
who had been above the cut-off at Baseline 2. This is illustrated by the mean and confidence 









Figure 9. Modified Brinley plots showing the effect of micronutrient intervention on 
anxiety as measured by the SDQ. 
 
3.3 Comparison of Change over Time in Group Mean Data 
Tables 4, 5 and 6 present the group mean, standard error of the mean (SEM), the 
mean difference between the respective experimental phases, the 95% Confidence Interval 
(95% CI) for the mean difference, the t value for non-independent samples and the Effect 
Size (Cohen’s d for non-independent samples) for the SCARED, PEDS, CGAS, RCMAS, 
MYMOP, MFQ, CDRS and SDQ.  
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3.3.1 Baseline comparisons and multiple baseline analyses. A multiple baseline 
design allows researchers to examine any differences in symptom stability between groups 
with different length baseline periods over the entire baseline period. In doing this the 
researcher can determine if there was a decrease in symptoms prior to the intervention and 
how this decrease compares to decreases seen during the intervention phase. 
Analysis of stability over the baseline period. Table 4 compares initial baseline scores 
with final baseline scores to assess stability over the baseline period. Participants tended to 
have elevated scores in terms of clinical cut-offs throughout the baseline period on the 
primary measures (SCARED and PEDS). Scores on measures of mood (MFQ and CDRS) 
tended to be below the clinical cut-offs and remain so throughout the baseline period. Paired 
sample t-tests revealed that for the CGAS, RCMAS, MYMOP, MFQ and CDRS there were 
no statistically significant changes in scores over the baseline period. However, there were 
statistically significant decreases in anxiety over the baseline period on the SCARED and the 
PEDS. This somewhat compromises the multiple baseline design, given the SCARED and the 
PEDS are the primary measures of anxiety within the study, because it shows that there was a 
trend in baseline that was in the direction expected during treatment. However, as shown 
below in the pre-post treatment mean comparisons and demonstrated in the above modified 
Brinley plots, there was a clear change evident during the treatment phase that was 
considerably greater than the observed changes in baseline, and the treatment effect was 
replicated across participants, and across all dependent variables, providing strong evidence 
that the micronutrients did alter the children’s symptoms.  
Confidence intervals for the mean difference between initial and final baseline scores 
do range from approximately one point in difference to approximately 13 and nine points for 
the SCARED and PEDS respectively. This indicates that the true difference could be as little 
as one point between initial and final baseline for each of these measures. Furthermore, the 




mean difference 95% CI’s for the SCARED and PEDS are both large, indicating large 
variability amongst participants’ scores during the baseline period.  All 95% CI’s for the 
mean difference between initial and final baseline on the other measures shown in Table 3 
include 0 and thus the true mean difference may be 0, or a worsening in score over the 
baseline period. The effect sizes for the changes on the SCARED and the PEDS fell in the 
moderate range using Cohen’s (1992) criteria of 0.2 for a small effect, 0.5 for a medium 
effect and 0.8 for a large effect size. 
Baseline length comparisons. There were no notable trends in terms of differences 
between baseline scores when comparing the three different baseline length groups (group 
1=1 week baseline, group 2=2 week baseline and group 3=3 week baseline). Between group 
comparisons of the means and 95% CI’s for measures completed during baseline assessments 
were made at each time point and the mean and 95% CI for group one at initial baseline was 
compared to the mean and 95% CI for group two at initial baseline and these both then 
compared with the mean and 95% CI for group three at initial baseline.  On the child rated 
RCMAS and MYMOP there was a tendency toward a difference between scores for group 1 
compared to group 3. There was no overlap between 95% CI’s for group 1 and group 3 on the 
RCMAS at initial baseline. This indicates that the true mean for these groups cannot be the 
same and thus that group 3 was more severe in terms of child-rated anxiety compared to 
group 1 at initial baseline. On the MYMOP there was no overlap in the 95% CI’s for group 1 
compared to group 3 at final baseline. This indicates that the true mean for these groups 
cannot be the same and thus that group 3 was more severe in terms of child-rated symptoms 
of anxiety when compared to group 1 at final baseline.  































































































3.3.2 Baseline versus post-intervention comparisons. Table 5 compares final 
baseline and post-trial means for the same set of variables as Table 4, as well as the SDQ. 
Each participant’s final baseline data point was used for these baseline-to-treatment phase 
comparisons (as noted above,  baseline measures were taken at the start and then again either 
one, two or three weeks later, prior to the intervention). Paired sample t-tests were completed 
using intent-to-treat analysis and final baseline data points (due to the trend in reductions seen 
over the baseline period and illustrated in Table 4), making for a more conservative analysis 
as discussed above (3.2). The average participant tended to improve to a point where they 
were no longer within the clinically significant range over the treatment phase on the 
SCARED and PEDS. There was an average improvement of 10 points on the CGAS over the 
intervention phase as well as further decreases in scores on all secondary measures, although 
the mean score for each of these measures was not elevated at final baseline. 
Paired sample t-tests revealed statistically significant improvements on all nine 
outcome measures (Table 5). Of particular note are the changes observed on the primary 
measures of the study. These are the parent-rated measures of anxiety (SCARED and PEDS) 
and the clinician-rated measure of level of functioning (CGAS). While the paired sample t-
tests for the primary measures were all statistically significant, the effect sizes for these 
measures were also large, confirming clinically meaningful change. The effect sizes for the 
secondary measures range from moderate to large in size, also indicating clinically 
meaningful change from final baseline to post-intervention.  
  








































































3.3.3 Post-intervention versus follow-up comparisons. Table 6 compares post-trial 
and follow-up means for the same set of variables as Table 5. Table 6 illustrates that, based 
on the six participants followed for three months post-trial, there were no significant changes 
found between the end of trial and three month follow-up on any measure. This indicates that 
although participants did not continue to improve, on average they also did not lose the gains 
they had made by the end of the trial. Four out of six (66.7%) participants continued to take 
EMP+ (or Daily Essential Nutrients, a newer version of EMP+ with very similar ingredients) 
at follow-up. These participants took micronutrients at least every third day at a lower dose 
than during the intervention phase and more regularly during times of stress. In addition, one 
other participant had been taking EMP+ for the majority of the follow-up period. This 
participant was off the EMP+ at the time of follow-up and stated they were planning to 





































































































































3.4 Further Analyses 
Responder status demonstrates the percentage of participants who during baseline 
were above clinical cut-off for a measure and moved to below that clinical cut-off following 
intervention with micronutrients. These analyses were completed using the final baseline data 
in order to give an accurate representation of the impact of the micronutrient intervention.  
Seven out of the 10 (70%) participants who were within clinical range at final 
baseline as measured by the SCARED responded positively to the intervention, such that 
their level of anxiety decreased from the clinical range to within normal range. Five out of the 
14 (35.7%) participants who were within clinical range at final baseline as measured by the 
PEDS responded positively to the intervention, such that their level of anxiety decreased from 
clinical range to within normal range.  
Two out of the four (50%) participants who were within clinical range at final 
baseline as measured by the RCMAS responded positively to the intervention, such that their 
level of anxiety decreased from clinical range to within normal range. Two out of the four 
(50%) participants who were within clinical range at final baseline as measured by the parent-
rated MFQ responded positively to the intervention, such that their mood symptoms 
decreased to be within normal range. No participants were elevated in mood at final baseline 
or the end of trial as measured by the clinician-rated CDRS and thus responder status as 
determined by this measure cannot be calculated. All three (100%) of the participants who 
were within clinical range at final baseline as measured by the SDQ responded positively to 
the intervention, such that their level of difficulties decreased from clinical range to within 
normal range. 
Further analyses show that nine (64%) of the full sample of participants improved 
moderately or markedly from baseline as measured by the clinician-rated Overall Clinical 
Impression measure.  





4.1 Summary of Findings 
This innovative research points to a completely new approach to treating anxiety in 
children. It found micronutrient intervention resulted in clinically significant decreases in 
anxiety, as well as improvements in overall functioning, amongst a sample of children who 
were suffering from clinically elevated anxiety. This is consistent with other reports from the 
literature on micronutrient interventions for anxiety in adults and what little research has been 
published in terms of micronutrient interventions for anxiety in children. This study found 
there were statistically significant changes in favour of micronutrient intervention for all 
dependent variables, as demonstrated by modified Brinley plots and comparison of means. 
Eleven participants completed the trial, one participant withdrew following the final baseline 
assessment, another following week two of the intervention phase and another following 
week six of the intervention phase.  
The current sample reflected a group of children with clinically significant levels of 
anxiety, many of whom experienced onset or worsening in anxiety following the Canterbury 
earthquakes. Ten of the final fourteen participants also met criteria for at least one DSM-IV 
anxiety disorder and all were experiencing clinically significant impairment in day-to-day 
functioning prior to starting the intervention.  
As predicted, the hypotheses were generally supported. The primary hypothesis 
proposed that micronutrient intervention would be associated with improvements in anxiety. 
This hypothesis was supported such that ten out of eleven participants who completed the 
intervention experienced a clinically significant decrease (e.g. they dropped below the 
clinical cut-off) in anxiety on the SCARED. Furthermore, five out of eleven of these same 
participants experienced a clinically significant decrease in anxiety on the PEDS. The 
remaining six participants all experienced a decrease but remained in the clinical range on the 




PEDS. Some quotes from participants illustrate the effect of the information in a qualitative 
way. For instance, at the end of the intervention phase, one caregiver commented that their 
child was “not reacting as much” and another caregiver that their child would “deal with 
things better without tantrums and tearfulness”. Another caregiver said their child was 
“happier and more animated”. 
Though the current study found there was a tendency for a slight decrease on some 
measures over the baseline period, with statistically significant decreases on the two primary 
measures of anxiety, there was a much steeper change in anxiety and overall functioning 
during the intervention phase. The fact that multiple replications of a treatment effect were 
seen across all dependent variables and consistently across participants reinforces this, 
particularly when considering the impact of compliance on improvement, such that compliant 
participants (those accurately following intervention protocol) improved more than those 
participants who did not follow the protocol. This demonstrates an effect of the intervention 
above that of regression to the mean or a natural tendency for people to improve over time.	  
The second hypothesis, that micronutrient intervention would be associated with 
improvement in overall functioning and in mood where mood was elevated at baseline, was 
also supported. Ten out of the eleven participants who completed the intervention 
experienced an improvement in every day functioning as measured by the CGAS. Only one 
participant was elevated in terms of mood at baseline (as measured by the MFQ) and this 
participant experienced a clinically significant decrease in mood following the intervention 
phase, such that they dropped to below the clinically significant cut-off on the MFQ. 
Intervention with micronutrients was associated with mild to moderate side-effects in 
five out of fourteen participants. The majority of adverse effects during the intervention were 
mild (e.g. gastrointestinal disturbance and nausea), with one participant experiencing side 
effects at a moderate level (gastrointestinal disturbance and nausea). All side effects were 




transitory or able to be remedied with small changes in diet or dosage, except for one 
participant who continued to experience mild nausea after taking the morning dose 
throughout the trial. No participant withdrew because of adverse effects.  
In terms of compliance, most participants (92%) were able to swallow the pills at the 
trial dose. Three participants took EMP+ at a lower dose (four to six pills per day) than 
recommended in the treatment protocol, but still achieved improvement in anxiety and 
overall functioning. Over half of the sample achieved at least an 80% compliance rate. Two 
participants who were non-compliant struggled to remember to take the pills regularly. 
Another could not swallow the pills but did not like the taste of the powder and thus took the 
micronutrient intermittently. Another did not experience a significant effect and so was not 
motivated to continue with what was seen as a “hassle”. The fifth participant who struggled 
with compliance developed glandular fever and missed a number of doses as a result of this 
illness.  
Despite documented benefit for participants, compliance was a struggle for some, 
highlighting the challenges associated with such a treatment. However, no participant 
withdrew because of problems associated with taking the actual micronutrients. One 
participant withdrew prior to week two of the intervention phase because of family illness, 
another following the week two appointment due to the trouble of visits and another 
following week six of the intervention phase due to family stress.  
It was observed that those participants with lower levels of anxiety initially found it 
easier to comply with the study protocol, as was demonstrated in the modified Brinley plots 
within the results section. These showed that compliant participants had lower levels of 
anxiety at baseline, as well as lower symptomatology on all measures but one (the RCMAS), 
when compared to non-compliant participants. These also showed that although there was 
sometimes a similar level of improvement between compliant and non-compliant 




participants, the non-compliant participants completed the study with more symptomatology 
than the compliant participants. There are many factors that could influence compliance such 
as SES, family stress and parental anxiety. A study by Dean, Wragg, Draper and McDermott 
(2011) investigated factors affecting poor compliance with psychotropic medication regimes 
in children. The authors found that lack of parent involvement, use of commentary 
medications and difficulty remembering doses all negatively affected adherence. Future 
research should investigate compliance and factors which make it more likely an individual 
will have difficulty with adherence. Future research should also aim to monitor and remove 
those factors, both before participants engage in an intervention and during the intervention 
phase, in order to make treatment effective for as many individuals as possible. 
The final hypothesis, that improvements would be maintained over the follow-up 
period if participants remained on EMP+, was also supported. Overall, little or no further 
improvement was seen between the end of the intervention phase and the three month follow-
up for the six participants who attended follow-up. Four of the six participants who attended 
follow-up continued to take EMP+ at least every third day at a lower dose than during the 
intervention phase, with continued positive effect. Another participant had been taking EMP+ 
for the majority of the period between the end of the trial and follow-up but had stopped prior 
to follow-up. 
The findings of the present study are consistent with previous reports investigating the 
effect of micronutrient intervention with EMP+ on anxiety in children and adults. 
Furthermore, this study replicated findings from a number of studies internationally which 
have demonstrated the positive effect of EMP+ on mental health problems such as OCD, 
bipolar disorder and ADHD (Gately & Kaplan, 2009; Kaplan et al., 2001; Kaplan et al., 2002; 
Kaplan et al., 2004; Kaplan et al., 2007; Mehl-Madrona et al., 2010; Popper, 2001; 
Rucklidge, 2009; Rucklidge et al., 2010; Rucklidge et al., 2011; Rucklidge et al., 2014). 




These studies have demonstrated a positive treatment response and side effects which are 
minor and transitory when compared to pharmacological treatment approaches. Furthermore, 
other studies investigating the impact of micronutrient formulas which are not EMP+ on 
anxiety and stress have also found a positive treatment response. It is difficult to compare 
these studies to each other and to those investigating the impact of EMP+ given the different 
formulas and dosages which are utilised in them. Even so, the overall findings indicate strong 
potential for the use of multi-ingredient micronutrient formulas, including EMP+, in the 
treatment of anxiety and stress in children, as well as adults.  
The current recommended protocol by the National Institute of Health and Care 
Excellence (NICE) for treating high anxiety and anxiety disorder in children is to trial 
psychotherapy followed by pharmacotherapy as a final resort treatment and only in cases 
where symptoms are moderate to severe (NICE, 2005). Furthermore, New Zealand guidelines 
published by The Werry Centre for Child and Adolescent Mental Health Workforce 
Development state there is an overall lack of efficacy about the use of selective serotonin 
reuptake inhibitors (SSRI; the main pharmacological medication utilised) for the treatment of 
child anxiety disorders, except in the case of OCD, where it is considered a “promising 
treatment” (Dunnachie, 2007).  In addition, it is well documented that pharmacotherapy is 
associated with side effects which are sometimes severe and distressing for the child 
(Birmaher et al., 2003). Furthermore, there is also very little research documenting the long 
term effect of psychiatric medication administration to children with anxiety disorders. Many 
drug trials only monitor participants for three months to one year, which is not enough time 
to be sure the drug does not negatively impact the child in anyway, particularly his or her 
development. Admittedly, there is also no research on the long-term efficacy and safety of 
micronutrients; however, it also may be, as was shown in the current study that children are 
able to reduce their dosage or take EMP+ intermittently, while stilling maintain a therapeutic 




effect, unlike with psychiatric medication. The current research suggests that micronutrient 
intervention has a less severe side effect profile than psychiatric medications and yet, is also 
effective at relieving anxiety. Thus, further research into the impact of micronutrient 
intervention on anxiety in children appears to be warranted. 
Furthermore, it is noted that micronutrients may actually have a quicker therapeutic 
effect than psychiatric medications for the treatment of child anxiety, as well as a similar 
length of therapeutic effect as psychotherapy. As discussed in the introduction, both Rynn et 
al. (2001) and Walkup et al. (2001) reported a general trend toward improvement in their 
medication trials but that it took nine weeks for there to be a difference between symptom 
severity for those taking fluoxetine compared to those taking placebo. This is the same length 
as a recommended course of psychotherapy. While the current study had no placebo group to 
compare the course of the intervention too, and thus cannot rule out these effects (the 
contribution of placebo effects to treatment effect found is discussed below), it may be that 
micronutrient intervention provides symptom relieve at a rate equal to psychotherapy (i.e. 
approximately eight weeks to clinically significant effects) and quicker than 
pharmacotherapy.  Future studies might examine these trajectories of improvement in terms 
of symptom relief between treatments, including placebo, in more detail. 
An explanation for the effect of multi-ingredient formulas may lie in the fact that 
nutrients do not work in isolation, but rather in combinations which lead to optimal 
functioning within the brain and body. Indeed, as discussed in the introduction, Mertz (1994) 
has argued that single-nutrient interventions may actually lead to deficiencies given the 
intertwined and complex nature of the role of micronutrients within bodily systems. Kaplan 
and colleagues’ (2007) review suggests that the multi-ingredient approach to nutritional 
supplementation is gaining support within the field of mental health. There have been a 
number of studies investigating the role of multi-ingredient formulas in the treatment of 




psychiatric disorders, such as the recently published double-blind randomised control trial by 
Rucklidge, Frampton, Gorman and Boggis (2014). 
As examined in the introduction, Kaplan and colleagues (2007) have discussed four 
conceptual frameworks for how micronutrients may act within the brain to alleviate the 
symptoms of mental health disorders, particularly of mood disorders. The authors propose 
that these models are not mutually exclusive or exhaustive but rather that they are compatible 
(Kaplan et al., 2007). The first model suggested that unstable mood may be the result of 
inborn errors in metabolism, which might affect enzyme or coenzyme reactions and thus 
brain function (Kaplan et al., 2007; Ames, 2004). Another model suggests problems with 
methylation processes that lead to deficient methylation rates. While methylation is essential 
to a number of processes within the brain, it may particularly affect neurotransmitter 
synthesis (Kaplan et al., 2007). B-vitamin deficiencies could have a role within this model via 
homocysteine metabolism, which can affect levels of SAMe within the brain, ultimately 
affecting neurotransmitter synthesis (Camfield et al., 2013; Papakostas et al., 2003).  
It has been well established that nutrient status can alter gene expression. Thus, 
nutrient deficiencies could result in alterations in the expression of genes involved in certain 
mental health disorders, of which a number have high heritability and therefore some genetic 
basis (Kaplan et al., 2007; Kaplan & Leung, 2011). Another model proposes that long-term 
deficiencies eventually lead to disorder over time (Kaplan et al., 2007). This model is based 
on Ames’s (2010) triage hypothesis which suggests the body naturally diverts nutritional 
resources to those functions necessary for survival when the body experiences nutrient 
deficiency, even if this is sometimes at the expense of long term health, which may 
eventually lead to disorder.  




Mitochondrial dysfunction has also been implicated via negatively affecting the 
energy metabolism of neurons and glial cells and thus having a flow on effect to other 
processes, such as synaptic communication (Rucklidge & Kaplan, 2013).  
These models and theories propose possible mechanisms behind the positive effect on 
psychiatric symptoms that is being observed in mental health and nutrition research using 
multi-ingredient micronutrient formulas. It may be that these models are all intertwined; 
indeed there is overlap among them. Furthermore, the consequence of the models is that some 
individuals may require more nutrients than available through diet, and at higher rates than 
recommended daily allowance, in order to function optimally. Furthermore, within this group 
of individuals, some people may need more nutrients than others. Perhaps this is why those in 
the compliant – low dose group within the present study experienced a treatment effect 
equivalent to those taking the recommended dose of EMP+, despite consuming a lesser 
amount of the intervention. This difference may be because of biological individuality in the 
amount of nutrients a person requires to function optimally, as has been acknowledged by 
Rucklidge and Kaplan (2013).  
 Another consideration is that it may be that some individuals are more vulnerable to 
the depletion of nutrients in soils and foods which has occurred over previous decades 
(Mayer, 1997; Thomson & Robinson, 1980; Ekholm et al., 2007), and thus require 
supplementation, perhaps because of one of the problems illustrated in the above models.  
In the 1920’s, the Western world was accepting of the idea that “imperfect” nutrition 
was very important in the expression of mental illness, with treatment usually involving 
improvements in diet (Kaplan & Leung, 2011). Yet today this idea seems foreign to many 
scientists and clinicians who dismiss it. What the literature is showing is that multi-ingredient 
formulas may be a viable way forward in terms of providing another treatment for mental 
illness.  






One limitation of the current study is the open label nature of the trial, making 
participants, caregivers and clinicians susceptible to expectancy effects. Although a placebo 
response cannot be ruled out given participants knew they were taking an active intervention, 
there are several reasons why it is unlikely to explain the therapeutic effects found.  
There were no therapeutic benefits seen for participants until at least two weeks after 
beginning EMP+, although more commonly at four weeks. Placebo effects are less strong 
when the illness has been present for some time, as is the case in the present study, where all 
participants had been experiencing problems with anxiety for some months at least (Cohen et 
al., 2010). Furthermore, 79% of the participants had undergone some type of treatment prior 
to entering the trial and had not experienced a significant treatment effect. It should also be 
considered that the follow-up data collected suggest changes in anxiety were maintained over 
at least three months. Cohen and colleagues (2010) also reported less of a placebo effect in 
samples which are predominantly Caucasian, as is true of the present study.  
Children with anxiety disorders, including OCD, have been shown to be less 
susceptible to placebo effects than those with major depression (Cohen et al., 2008). 
Furthermore, it was stressed to participants that the researcher did not know if the treatment 
would work. The literature on placebo effects in children demonstrates that children are more 
susceptible to the placebo effect than adolescents and adults, although this is not always true 
(Rutherford, et al., 2011). So while placebo effects cannot be ruled out, a number of reasons 
suggest these effects are unlikely to be responsible for the positive effect of the micronutrient 
intervention. As the current study is a pilot trial, the promising results do highlight the need 
for future placebo-controlled research into the effect of multi-ingredient micronutrient 
intervention for anxiety in a larger sample of children. 




Spontaneous remission should be considered, but given so many of the sample of 
participants experienced a positive effect and had been ill for so long, it is unlikely this is 
responsible for the treatment effect observed. 
Participation in research trials involves regular therapeutic input through contact with 
the researcher, including assessment of symptoms, empathic responses and assistance with 
remaining treatment compliant. The therapist effect could have contributed to the 
improvements seen in this current study. Again, most participants had undergone some type 
of previous treatment with a health professional without significant improvement. Yet it 
cannot be ruled out that the participant, and/or the caregiver, may have felt there was some 
improvement in anxiety simply through contact with the researcher. There was a significant 
decrease in anxiety on the SCARED and PEDS over the baseline period, which may indicate 
some susceptibility on the caregivers’ behalf to the therapist effect. However, this is unlikely 
to explain the strength of the changes in symptoms seen throughout the intervention, as 
contact with the researcher was kept to a minimum, occurring fortnightly unless there were 
other issues which necessitated contact more frequently and appointments were generally 
short (less than thirty minutes). Changes were also maintained over the follow-up period 
when there was no contact with the researcher. Furthermore, appointments were focused 
purely on assessment and improving compliance. Participants were not given psychological 
strategies to cope with their anxiety. 
Experimenter bias should also be considered as a potential contributor to the positive 
findings seen in the current study. However, this study utilised multi-informant data, with two 
of the three primary measures being parent-rated. 
Other factors which may explain some of the positive findings include improved daily 
routine and diet through needing to eat an adequate breakfast and evening meal, as well as 
drink plenty of water, in order to take the micronutrient correctly. These changes may have 




influenced mood and/or anxiety. Diet was not assessed however, so the extent of influence 
these changes may have had on the outcome cannot be determined. 
The small sample size is another limitation of the study. Such a sample size limits the 
generalizability of any results. Thus, further studies utilising a much larger sample, with a 
double-blind randomised controlled design, will be important in investigating whether these 
results do generalise to other samples and therefore potentially the population of children 
with anxiety.  
It should also be considered that this particular sample was unique in that previous 
treatments had not been effective at alleviating symptoms for eleven of the fourteen 
participants, including traditional treatments. This may actually be a strength of the study 
given the majority of participants did respond positively. 
Lastly, as noted above, the unanticipated reductions in symptom severity over the 
baseline period are another limitation of this study. However, it has been established that the 
changes seen in symptom severity over the intervention phase were much greater than any 
baseline changes. Kratochwill et al. (2010) suggest any fewer than three baseline data points 
cannot be used to show there was no effect on symptom severity over baseline. Thus, this 
should be remedied in any further research. Having a minimum of three probe points during 
the baseline phase is recommended to capture any systematic and natural fluctuations in 
anxiety, such that there would be an even clearer difference between baseline and 
intervention phases (Cooper et al., 2007; Kratochwill,et al., 2010). This would also determine 
if any reactivity to assessment levelled out of the course of the baseline period or if it 
continued over the whole baseline period. This could affect conclusions drawn about the 
effect of the intervention, such that if the level of reactivity reduced we could be much more 
confident in the effect of the intervention given this shows there would be less of an influence 
of assessment on the data collected.  






An important issue to consider in terms of feasibility is compliance with the treatment 
protocol. Difficulties with maintaining compliance included struggles with swallowing the 
pills, necessitating a move to using powder for two participants. This entails its own problems 
as it takes more time and effort to prepare the powder then for the child to drink it, than it 
does for the child to take four pills during the course of a meal. Other difficulties included 
remembering to take the pills and the after taste of the pills or powder. Also, another 
difficulty for some participants was adapting to taking the micronutrient with enough water 
and food so as not to cause stomach upsets. This sometimes required additional organisation 
on the caregiver’s behalf, as well as the child’s, in often already busy households.  
The cost of continuing the micronutrient intervention of the end of the trial is another 
important factor to consider. However, it was generally found that even low income families 
made this a priority when they saw how much EMP+ helped their child. Furthermore, there is 
a large commitment required not just of participants, but their families as well, in order to 
help the child be compliant, attend appointments and answer questionnaires.  
Challenges for the researchers included contacting caregivers to get them and their 
child to visit for appointments. Caregivers would often need to bring their other children with 
them or only be able to come on certain days because of children’s extra-curricular activities 
or work commitments. Communication via phone and email, as well as via text, was very 
helpful in this respect. 
Side effects associated with the intervention also impact on the feasibility of such 
research. Thirty-six per cent of participants experienced a side effect which may have been 
related to the intervention and for 80% of these participants the symptoms were mild. All side 
effects were transient, except for one participant. One issue with monitoring side effects in 




this particular sample was distinguishing between the physiological symptoms of anxiety and 
potential side effects of EMP+. It is common for children with anxiety to experience 
physiological symptoms which are similar to those side effects sometimes observed when 
taking EMP+. Baseline information on these particular symptoms was collected for the 
majority of participants and it was observed that these symptoms decreased for three 
participants over the course of the trial. This suggests that EMP+ was not associated with side 
effects in these participants but rather remedied physiological symptoms of anxiety. 
 
4.4 Further Research 
As people seek alternative treatments for mental health problems because of the 
limited availability of publically funded psychotherapy, the expense of attending 
psychotherapy privately, the modest efficacy of medications and the concerns about the side 
effects or the long-term impact of medication, further options will be essential to the 
consumer (Rucklidge & Kaplan, 2013). These options deserve to be explored to provide 
patients and families with alternatives which might suit them better.  
Further research on multi-ingredient micronutrient formulas should explore the long-
term safety and impact of these formulas over years. This might determine if people who 
continue to use these broad-based micronutrient interventions maintain any benefits in terms 
of their mental health, but also experience benefits in terms of their general health or 
increased resiliency, as well as any potential adverse effects. It will be particularly important 
that randomised controlled trials are conducted investigating the impact of micronutrient 
intervention for a number of mental health problems and in numerous different samples. 
While it is difficult to compare different multi-ingredient formulas, further investigation of 
dosage rates and particular combinations of ingredients may also be important. 




As Rucklidge and Kaplan (2013) stated in a review published in Expert Review of 
Neurotherapeutics, this type of intervention may not be appropriate for all people, just as 
doctors would not provide “insulin to someone whose pancreas produces sufficient amounts”. 
Rucklidge and Kaplan (2013) go on to propose that it would be better to know if an 
individual would be suited to micronutrient intervention before providing it, rather than 
administering the intervention to all, but that current scientific knowledge and tests are not 
able to determine a person’s individual metabolic needs as yet. Perhaps as this knowledge 
and the knowledge about how micronutrient formulas act to affect mental health advances 
this sort of testing will become possible. This might allow treatment, including specific 
formulas and dosage rates, to be tailored individually based on an individual’s unique 
biological and genetic make-up. 
Future research trials should continue to investigate the risk/benefit ratios of 
micronutrient interventions and compare these to other treatment options. These trials might 
focus on comparing not only broad-based micronutrient formulas to placebo but also to 
standard psychopharmacological treatment as well as psychotherapy. An interesting 
comparison would be to provide micronutrient intervention as an adjunct to psychotherapy, 
compared with other treatment options, such as psychotherapy alone. Furthermore, it may be 
that micronutrients are suitable for some individuals in the short-term but not necessary in the 
long term, for instance those whose anxiety was triggered by an acute stressor such as an 
earthquake; but that different dosages and regimes are necessary for other individuals, such as 
those whose anxiety is chronic in nature or who have anxious temperaments. For instance, 
future research might find that psychotherapy, to teach individuals with chronic illness 
strategies to manage their anxiety, alongside micronutrients, increases the effectiveness of 
psychotherapy and the speed at which symptoms decrease. This group of individuals may 
require micronutrients at a higher dose or on a more long-term basis. 




Investigating the effect of probiotic supplementation alongside micronutrient 
intervention and the effect of this combination on, in particular stress and anxiety, given their 
impact on the gut, but also for other mental health problems, may be another avenue for 
exploration. Rucklidge and Kaplan (2013) anticipate that gut health will become increasingly 
important within the field of nutrition and mental health in order to maximise treatment 
response through ensuring optimal absorption of micronutrients. 
 
4.5 Conclusion 
In conclusion, the results of the current study provide evidence that multi-ingredient 
micronutrient formulas have potential as a treatment option for children suffering from 
problems with anxiety. The results also give further support to studies which indicate that 
micronutrient treatment is associated with improvements in a range of psychiatric symptoms 
and overall functioning. It is important that clinicians and researchers remain open to other 
treatment options, such as micronutrient intervention, in order to provide the best care for 
clients.  Further studies investigating the effect of broad-based micronutrient interventions as 
a treatment for psychiatric disorders may provide more support for the use of micronutrients 
within mental health. This would afford clients another individual or additional treatment 
option. As physiological knowledge increases about the mechanisms of action for these 
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Appendix A: Ingredient List of EMPowerplus 
 
1 capsule 4 capsules 8 capsules Ingredient 
384.0 IU 1536.0 IU 3072.0 IU Vitamin A  
40.0 mg 160.0 mg 320.0 mg Vitamin C  
96.0 IU 384.0 IU 768.0 IU Vitamin D  
24.0 IU 96.0 IU 192.0 IU Vitamin E   
1.2 mg 4.8 mg 9.6 mg Vitamin B1  
0.9 mg 3.6 mg 7.2 mg Vitamin B2  
6.0 mg 24.0 mg 48.0 mg Vitamin B3  
1.4 mg 5.8 mg 11.5 mg Vitamin B5  
2.4 mg 9.6 mg 19.2 mg Vitamin B6  
96.0 ug 384.0 ug 768.0 ug Vitamin B9  
60.0 ug 240.0 ug 480.0 ug Vitamin B12  
72.0 ug 288.0 ug 576.0 ug Vitamin H  
88.0 mg 352.0 mg 704.0 mg Calcium  
0.9 mg 3.7 mg 7.3 mg Iron  
56.0 mg 224.0 mg 448.0 mg Phosphorus 
13.6 ug 54.4 ug 108.8 ug Iodine  
40.0 mg 160.0 mg 320.0 mg Magnesium 
3.2 mg 12.8 mg 25.6 mg Zinc 
13.6 ug 54.4 ug 108.8 ug Selenium 
0.5 mg 1.9 mg 3.8 mg Copper 
0.6 mg 2.6 mg 5.1 mg Manganese 
41.6 ug 166.4 ug 332.8 ug Chromium  
9.6 ug 38.4 ug 76.8 ug Molybdenum  
16.0 mg 64.0 mg 128.0 mg Potassium 




24.0 mg 96.0 mg 192.0 mg dl-phenylalanine 
12.0 mg 48.0 mg 96.0 mg glutamine 
16.0 mg 64.0 mg 128.0 mg citrus bioflavanoids 
3.0 mg 12.0 mg 24.0 mg grape seed 
36.0 mg 144.0 mg 288.0 mg choline bitartrate 
12.0 mg 48.0 mg 96.0 mg Inositol 
2.4 mg 9.6 mg 19.2 mg ginkgo biloba 
4.0 mg 16.0 mg 32.0 mg methionine 
1.4 mg 5.5 mg 11.0 mg germanium sesquioxide 
160.0 ug 640.0 ug 1280.0 ug Boron 
2.0 ug 7.8 ug 15.7 ug Nickel 
79.6 ug 318.4 ug 636.8 ug vanadium 
111.0  444.1  888.2  Proprietary Total 




Appendix B: Screening Questionnaire for Participation in the Current Study 
 
Child	  Anxiety	  and	  Stress	  Screening	  Questionnaire	  
	  
Q52	  This	  study	  aims	  to	  investigate	  the	  impact	  of	  taking	  a	  daily	  micronutrient	  formula	  on	  anxiety	  and	  
stress	  in	  Canterbury	  children	  aged	  8	  to	  11	  years	  old.	  If	  you	  feel	  your	  child	  experiences	  a	  significant	  
amount	  of	  stress	  or	  anxiety	  regularly	  then	  this	  study	  may	  be	  able	  help.	  The	  following	  survey	  is	  a	  
screening	  questionnaire	  to	  determine	  if	  your	  child's	  difficulties	  make	  them	  eligible	  to	  take	  part	  in	  the	  
study.	  	  	  	  	  This	  study	  has	  been	  approved	  by	  the	  University	  of	  Canterbury	  Human	  Ethics	  Committee	  and	  
the	  Upper	  South	  A	  Regional	  Ethics	  Committee.	  If	  you	  would	  like	  to	  know	  more	  about	  the	  study	  you	  
can	  contact	  the	  researcher	  at	  ellen.sole@pg.canterbury.ac.nz	  
	  
	  
Q1	  Please	  provide	  your	  name	  and	  contact	  details	  below	  
Name	  (1)	  
Address	  (2)	  
Address	  2	  (3)	  
City	  (4)	  
Contact	  number	  (5)	  
Email	  (6)	  
	  
Q4	  Please	  provide	  the	  name	  and	  age	  of	  your	  child	  below	  
Child's	  first	  name	  (1)	  
Child's	  age	  (2)	  
	  
	  
Q56	  The	  next	  questions	  pertain	  to	  the	  eligibility	  criteria	  which	  allow	  your	  child	  to	  take	  part	  in	  the	  
study.	  
	  
Q57	  Does	  your	  child	  eat	  at	  least	  a	  snack	  two	  times	  a	  day?	  
m Yes	  (1)	  
m No	  (2)	  
	  
Answer	  If	  Does	  your	  child	  eat	  at	  least	  a	  snack	  two	  times	  a	  day?	  No	  Is	  Selected	  
Q62	  Participant's	  in	  the	  study	  must	  be	  able	  to	  eat	  at	  least	  a	  snack	  before	  taking	  the	  micronutrients.	  If	  
the	  micronutrients	  are	  taken	  on	  an	  empty	  stomach	  they	  can	  cause	  nausea	  and	  other	  minor	  side	  
effects.	  As	  such	  we	  require	  participants	  to	  be	  able	  to	  eat	  at	  least	  two	  snacks	  a	  day,	  one	  before	  each	  
dose	  of	  micronutrients,	  which	  are	  taken	  as	  4	  pills	  twice	  per	  day.	  	  	  	  	  Is	  your	  child	  is	  able	  and	  willing	  to	  
eat	  at	  least	  a	  snack	  two	  times	  a	  day?	  
m Yes	  (1)	  
m No	  (2)	  
	  
Answer	  If	  Participant's	  in	  the	  study	  must	  be	  able	  to	  eat	  at	  least	  a...	  No	  Is	  Selected	  
Q75	  Thank-­‐you	  for	  taking	  this	  questionnaire.	  Your	  answers	  indicate	  one	  of	  the	  studies	  exclusion	  
criteria	  has	  been	  met.	  Unfortunately	  this	  means	  your	  child	  is	  not	  eligible	  to	  participate	  in	  the	  trial.	  If	  
you	  have	  any	  questions	  or	  concerns	  please	  contact	  the	  researcher	  at	  
ellen.sole@pg.canterbury.ac.nz.	  	  	  	  	  Thank-­‐you	  for	  your	  time.	  
	  
If	  Thank-­‐you	  for	  taking	  this	  q...	  Is	  Displayed,	  Then	  Skip	  To	  End	  of	  Survey	  




Q58	  Does	  your	  child	  have	  a	  neurological	  disorder,	  serious	  medical	  condition	  that	  would	  require	  
treatment	  throughout	  his/her	  time	  in	  the	  study	  or	  mineral	  metabolism	  abnormality?	  
m Yes	  (1)	  
m No	  (2)	  
	  
Answer	  If	  Does	  your	  child	  have	  a	  neurological	  disorder,	  serious	  med...	  Yes	  Is	  Selected	  
Q76	  Thank-­‐you	  for	  taking	  this	  questionnaire.	  Your	  answers	  indicate	  one	  of	  the	  studies	  exclusion	  
criteria	  has	  been	  met.	  Unfortunately	  this	  means	  your	  child	  is	  not	  eligible	  to	  participate	  in	  the	  trial.	  If	  
you	  have	  any	  questions	  or	  concerns	  please	  contact	  the	  researcher	  
ellen.sole@pg.canterbury.ac.nz.	  	  	  	  	  Thank-­‐you	  for	  your	  time.	  
	  
If	  Thank-­‐you	  for	  taking	  this	  q...	  Is	  Displayed,	  Then	  Skip	  To	  End	  of	  Survey	  
	  
Q59	  Does	  your	  child	  have	  known	  allergies	  to	  any	  of	  the	  following?	  These	  are	  the	  ingredients	  within	  
the	  micronutrient	  formula	  taken	  by	  participants	  in	  the	  study.	  	  	  	  	  	  	  
Vitamin	  A	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Calcium	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  dl-­‐phenylalanine	  	  
	  Vitamin	  C	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Iron	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Glutamine	  	  	  
Vitamin	  D	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Phosphorus	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Citrus	  bioflavonoids	  
	  	  Vitamin	  E	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Iodine	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Grape	  seed	  	  	  
Vitamin	  B1	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Magnesium	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Choline	  bitartrate	  	  	  
Vitamin	  B2	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Zinc	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Inositol	  	  	  
Vitamin	  B3	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Selenium	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Ginkgo	  biloba	  	  	  
Vitamin	  B5	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Copper	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Methionine	  	  	  
Vitamin	  B6	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Managnese	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Germanium	  sesquioxide	  
	  Vitamin	  B9	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Chromium	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Boron	  	  	  
Vitamin	  B12	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Molybdenum	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Nickel	  	  	  
Vitamin	  H	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Potassium	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Vanadium	  
m Yes	  (1)	  
m No	  (2)	  
	  
Answer	  If	  Does	  your	  child	  have	  known	  allergies	  to	  any	  of	  the	  follow...	  Yes	  Is	  Selected	  
Q77	  Thank-­‐you	  for	  taking	  this	  questionnaire.	  Your	  answers	  indicate	  one	  of	  the	  studies	  exclusion	  
criteria	  has	  been	  met.	  Unfortunately	  this	  means	  your	  child	  is	  not	  eligible	  to	  participate	  in	  the	  trial.	  If	  
you	  have	  any	  questions	  or	  concerns	  please	  contact	  the	  researcher	  at	  
ellen.sole@pg.canterbury.ac.nz.	  	  	  	  	  Thank-­‐you	  for	  your	  time.	  
	  
If	  Thank-­‐you	  for	  taking	  this	  q...	  Is	  Displayed,	  Then	  Skip	  To	  End	  of	  Survey	  
	  
Q60	  Does	  your	  child	  take	  any	  medication?	  
m Yes	  (1)	  
m No	  (2)	  
	  
Answer	  If	  Does	  your	  child	  take	  any	  medication?	  Yes	  Is	  Selected	  
Q67	  Please	  provide	  details	  of	  the	  medication	  name,	  dosage	  and	  reason	  for	  prescription	  below.	  
	  




Answer	  If	  Please	  provide	  details	  of	  the	  medication	  below.	  Text	  Response	  Is	  Displayed	  
Q68	  Certain	  medications	  are	  known	  to	  interact	  with	  the	  micronutrients	  taken	  in	  the	  study.	  A	  
researcher	  will	  contact	  you	  about	  eligibility	  to	  take	  part	  in	  the	  study	  after	  reviewing	  these	  
medications.	  Please	  continue	  on	  with	  the	  remainder	  of	  the	  questionnaire.	  
	  
Q61	  Does	  your	  child	  take	  any	  nutritional	  or	  herbal	  supplements?	  
m Yes	  (1)	  
m No	  (2)	  
	  
Answer	  If	  Does	  your	  child	  take	  any	  nutritional	  or	  herbal	  supplements?	  Yes	  Is	  Selected	  
Q69	  Please	  provide	  details	  of	  the	  supplement	  consumption	  below.	  Include	  dosage,	  reason	  for	  taking	  
and	  how	  long	  your	  child	  has	  been	  taking	  the	  supplement.	  
	  
Q3	  The	  questions	  below	  pertain	  to	  your	  child's	  everyday	  experiences.	  Please	  answer	  as	  truthfully	  
and	  openly	  as	  possible.	  
	  
Q5	  When	  my	  child	  feels	  frightened,	  it	  is	  hard	  for	  him/her	  to	  breathe.	  
m Not	  True	  or	  Hardly	  Ever	  True	  (0)	  
m Somewhat	  True	  or	  Sometimes	  True	  (1)	  
m Very	  True	  or	  Often	  True	  (2)	  
	  
Q6	  My	  child	  gets	  headaches	  when	  he/she	  is	  at	  school.	  
m Not	  True	  or	  Hardly	  Ever	  True	  (0)	  
m Somewhat	  True	  or	  Sometimes	  True	  (1)	  
m Very	  True	  or	  Often	  True	  (2)	  
	  
Q7	  My	  child	  doesn’t	  like	  to	  be	  with	  people	  he/she	  doesn’t	  know	  well.	  
m Not	  True	  or	  Hardly	  Ever	  True	  (0)	  
m Somewhat	  True	  or	  Sometimes	  True	  (1)	  
m Very	  True	  or	  Often	  True	  (2)	  
	  
Q8	  My	  child	  gets	  scared	  if	  he/she	  sleeps	  away	  from	  home.	  
m Not	  True	  or	  Hardly	  Ever	  True	  (0)	  
m Somewhat	  True	  or	  Sometimes	  True	  (1)	  
m Very	  True	  or	  Often	  True	  (2)	  
	  
Q9	  My	  child	  worries	  about	  other	  people	  liking	  him/her.	  
m Not	  True	  or	  Hardly	  Ever	  True	  (0)	  
m Somewhat	  True	  or	  Sometimes	  True	  (1)	  
m Very	  True	  or	  Often	  True	  (2)	  
	  
Q10	  When	  my	  child	  gets	  frightened,	  he/she	  feels	  like	  passing	  out.	  
m Not	  True	  or	  Hardly	  Ever	  True	  (0)	  
m Somewhat	  True	  or	  Sometimes	  True	  (1)	  
m Very	  True	  or	  Often	  True	  (2)	  
	  
	   	  




Q11	  My	  child	  is	  nervous.	  
m Not	  True	  or	  Hardly	  Ever	  True	  (0)	  
m Somewhat	  True	  or	  Sometimes	  True	  (1)	  
m Very	  True	  or	  Often	  True	  (2)	  
	  
Q12	  My	  child	  follows	  me	  wherever	  I	  go.	  
m Not	  True	  or	  Hardly	  Ever	  True	  (0)	  
m Somewhat	  True	  or	  Sometimes	  True	  (1)	  
m Very	  True	  or	  Often	  True	  (2)	  
	  
Q13	  People	  tell	  me	  that	  my	  child	  looks	  nervous.	  
m Not	  True	  or	  Hardly	  Ever	  True	  (0)	  
m Somewhat	  True	  or	  Sometimes	  True	  (1)	  
m Very	  True	  or	  Often	  True	  (2)	  
	  
Q14	  My	  child	  feels	  nervous	  with	  people	  he/she	  doesn’t	  know	  well.	  
m Not	  True	  or	  Hardly	  Ever	  True	  (0)	  
m Somewhat	  True	  or	  Sometimes	  True	  (1)	  
m Very	  True	  or	  Often	  True	  (2)	  
	  
Q15	  My	  child	  gets	  stomachaches	  at	  school.	  
m Not	  True	  or	  Hardly	  Ever	  True	  (0)	  
m Somewhat	  True	  or	  Sometimes	  True	  (1)	  
m Very	  True	  or	  Often	  True	  (2)	  
	  
Q16	  When	  my	  child	  gets	  frightened,	  he/she	  feels	  like	  he/she	  is	  going	  crazy.	  
m Not	  True	  or	  Hardly	  Ever	  True	  (0)	  
m Somewhat	  True	  or	  Sometimes	  True	  (1)	  
m Very	  True	  or	  Often	  True	  (2)	  
	  
Q17	  My	  child	  worries	  about	  sleeping	  alone.	  
m Not	  True	  or	  Hardly	  Ever	  True	  (0)	  
m Somewhat	  True	  or	  Sometimes	  True	  (1)	  
m Very	  True	  or	  Often	  True	  (2)	  
	  
Q18	  My	  child	  worries	  about	  being	  as	  good	  as	  other	  kids.	  
m Not	  True	  or	  Hardly	  Ever	  True	  (0)	  
m Somewhat	  True	  or	  Sometimes	  True	  (1)	  
m Very	  True	  or	  Often	  True	  (2)	  
	  
Q19	  When	  he/she	  gets	  frightened,	  he/she	  feels	  like	  things	  are	  not	  real.	  
m Not	  True	  or	  Hardly	  Ever	  True	  (0)	  
m Somewhat	  True	  or	  Sometimes	  True	  (1)	  
m Very	  True	  or	  Often	  True	  (2)	  
	  




Q20	  My	  child	  has	  nightmares	  about	  something	  bad	  happening	  to	  his/her	  parents.	  	  	  
m Not	  True	  or	  Hardly	  Ever	  True	  (0)	  
m Somewhat	  True	  or	  Sometimes	  True	  (1)	  
m Very	  True	  or	  Often	  True	  (2)	  
	  
Q21	  My	  child	  worries	  about	  going	  to	  school.	  
m Not	  True	  or	  Hardly	  Ever	  True	  (0)	  
m Somewhat	  True	  or	  Sometimes	  True	  (1)	  
m Very	  True	  or	  Often	  True	  (2)	  
	  
Q22	  When	  my	  child	  gets	  frightened,	  his/her	  heart	  beats	  fast.	  
m Not	  True	  or	  Hardly	  Ever	  True	  (0)	  
m Somewhat	  True	  or	  Sometimes	  True	  (1)	  
m Very	  True	  or	  Often	  True	  (2)	  
	  
Q25	  He/she	  gets	  shaky.	  
m Not	  True	  or	  Hardly	  Ever	  True	  (0)	  
m Somewhat	  True	  or	  Sometimes	  True	  (1)	  
m Very	  True	  or	  Often	  True	  (2)	  
	  
Q26	  My	  child	  has	  nightmares	  about	  something	  bad	  happening	  to	  him/her.	  
m Not	  True	  or	  Hardly	  Ever	  True	  (0)	  
m Somewhat	  True	  or	  Sometimes	  True	  (1)	  
m Very	  True	  or	  Often	  True	  (2)	  
	  
Q27	  My	  child	  worries	  about	  things	  working	  out	  for	  him/her.	  
m Not	  True	  or	  Hardly	  Ever	  True	  (0)	  
m Somewhat	  True	  or	  Sometimes	  True	  (1)	  
m Very	  True	  or	  Often	  True	  (2)	  
	  
Q28	  When	  my	  child	  gets	  frightened,	  he/she	  sweats	  a	  lot.	  
m Not	  True	  or	  Hardly	  Ever	  True	  (0)	  
m Somewhat	  True	  or	  Sometimes	  True	  (1)	  
m Very	  True	  or	  Often	  True	  (2)	  
	  
Q29	  My	  child	  is	  a	  worrier.	  
m Not	  True	  or	  Hardly	  Ever	  True	  (0)	  
m Somewhat	  True	  or	  Sometimes	  True	  (1)	  
m Very	  True	  or	  Often	  True	  (2)	  
	  
Q30	  My	  child	  gets	  really	  frightened	  for	  no	  reason	  at	  all.	  
m Not	  True	  or	  Hardly	  Ever	  True	  (0)	  
m Somewhat	  True	  or	  Sometimes	  True	  (1)	  
m Very	  True	  or	  Often	  True	  (2)	  
	  




Q31	  My	  child	  is	  afraid	  to	  be	  alone	  in	  the	  house.	  
m Not	  True	  or	  Hardly	  Ever	  True	  (0)	  
m Somewhat	  True	  or	  Sometimes	  True	  (1)	  
m Very	  True	  or	  Often	  True	  (2)	  
	  
Q32	  It	  is	  hard	  for	  my	  child	  to	  talk	  with	  people	  he/she	  doesn’t	  know	  well.	  
m Not	  True	  or	  Hardly	  Ever	  True	  (0)	  
m Somewhat	  True	  or	  Sometimes	  True	  (1)	  
m Very	  True	  or	  Often	  True	  (2)	  
	  
Q33	  When	  my	  child	  gets	  frightened,	  he/she	  feels	  like	  he/she	  is	  choking.	  
m Not	  True	  or	  Hardly	  Ever	  True	  (0)	  
m Somewhat	  True	  or	  Sometimes	  True	  (1)	  
m Very	  True	  or	  Often	  True	  (2)	  
	  
Q34	  People	  tell	  me	  that	  my	  child	  worries	  too	  much.	  
m Not	  True	  or	  Hardly	  Ever	  True	  (0)	  
m Somewhat	  True	  or	  Sometimes	  True	  (1)	  
m Very	  True	  or	  Often	  True	  (2)	  
	  
Q35	  My	  child	  doesn’t	  like	  to	  be	  away	  from	  his/her	  family.	  
m Not	  True	  or	  Hardly	  Ever	  True	  (0)	  
m Somewhat	  True	  or	  Sometimes	  True	  (1)	  
m Very	  True	  or	  Often	  True	  (2)	  
	  
Q36	  My	  child	  is	  afraid	  of	  having	  anxiety	  (or	  panic)	  attacks.	  
m Not	  True	  or	  Hardly	  Ever	  True	  (0)	  
m Somewhat	  True	  or	  Sometimes	  True	  (1)	  
m Very	  True	  or	  Often	  True	  (2)	  
	  
Q37	  My	  child	  worries	  that	  something	  bad	  might	  happen	  to	  his/her	  parents.	  	  
m Not	  True	  or	  Hardly	  Ever	  True	  (0)	  
m Somewhat	  True	  or	  Sometimes	  True	  (1)	  
m Very	  True	  or	  Often	  True	  (2)	  
	  
Q38	  My	  child	  feels	  shy	  with	  people	  he/she	  doesn’t	  know	  well.	  
m Not	  True	  or	  Hardly	  Ever	  True	  (0)	  
m Somewhat	  True	  or	  Sometimes	  True	  (1)	  
m Very	  True	  or	  Often	  True	  (2)	  
	  
Q39	  My	  child	  worries	  about	  what	  is	  going	  to	  happen	  in	  the	  future.	  
m Not	  True	  or	  Hardly	  Ever	  True	  (0)	  
m Somewhat	  True	  or	  Sometimes	  True	  (1)	  
m Very	  True	  or	  Often	  True	  (2)	  
	  




Q40	  When	  my	  child	  gets	  frightened,	  he/she	  feels	  like	  throwing	  up.	  
m Not	  True	  or	  Hardly	  Ever	  True	  (0)	  
m Somewhat	  True	  or	  Sometimes	  True	  (1)	  
m Very	  True	  or	  Often	  True	  (2)	  
	  
Q41	  My	  child	  worries	  about	  how	  well	  he/she	  does	  things.	  
m Not	  True	  or	  Hardly	  Ever	  True	  (0)	  
m Somewhat	  True	  or	  Sometimes	  True	  (1)	  
m Very	  True	  or	  Often	  True	  (2)	  
	  
Q42	  My	  child	  is	  scared	  to	  go	  to	  school.	  
m Not	  True	  or	  Hardly	  Ever	  True	  (0)	  
m Somewhat	  True	  or	  Sometimes	  True	  (1)	  
m Very	  True	  or	  Often	  True	  (2)	  
	  
Q43	  My	  child	  worries	  about	  things	  that	  have	  already	  happened.	  
m Not	  True	  or	  Hardly	  Ever	  True	  (0)	  
m Somewhat	  True	  or	  Sometimes	  True	  (1)	  
m Very	  True	  or	  Often	  True	  (2)	  
	  
Q44	  When	  my	  child	  gets	  frightened,	  he/she	  feels	  dizzy.	  
m Not	  True	  or	  Hardly	  Ever	  True	  (0)	  
m Somewhat	  True	  or	  Sometimes	  True	  (1)	  
m Very	  True	  or	  Often	  True	  (2)	  
	  
Q45	  My	  child	  feels	  nervous	  when	  he/she	  is	  with	  other	  children	  or	  adults	  and	  he/she	  has	  to	  do	  
something	  while	  they	  watch	  him/her	  (for	  example:	  read	  aloud,	  speak,	  play	  a	  game,	  play	  a	  sport.)	  
m Not	  True	  or	  Hardly	  Ever	  True	  (0)	  
m Somewhat	  True	  or	  Sometimes	  True	  (1)	  
m Very	  True	  or	  Often	  True	  (2)	  
	  
Q46	  My	  child	  feels	  nervous	  when	  he/she	  is	  going	  to	  parties,	  dances,	  or	  any	  place	  where	  there	  will	  be	  
people	  that	  he/she	  doesn’t	  know	  well.	  
m Not	  True	  or	  Hardly	  Ever	  True	  (0)	  
m Somewhat	  True	  or	  Sometimes	  True	  (1)	  
m Very	  True	  or	  Often	  True	  (2)	  
	  
Q47	  My	  child	  is	  shy.	  
m Not	  True	  or	  Hardly	  Ever	  True	  (0)	  
m Somewhat	  True	  or	  Sometimes	  True	  (1)	  
m Very	  True	  or	  Often	  True	  (2)	  
	  
Q49	  If	  there	  are	  any	  comments	  you	  would	  like	  to	  make,	  please	  do	  so	  below.	  
	  
	   	  




Q74	  Thank-­‐you	  for	  completing	  this	  questionnaire.	  The	  researcher	  will	  be	  in	  contact	  with	  you	  as	  soon	  
as	  possible	  about	  whether	  your	  child	  meets	  eligibility	  criteria	  to	  allow	  them	  to	  participate	  in	  the	  
study.	  If	  you	  have	  any	  questions	  in	  the	  meantime,	  feel	  free	  to	  email	  the	  researcher	  at	  
ellen.sole@pg.canterbury.ac.nz.	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What	  is	  the	  purpose	  of	  the	  study?	  
Your	  child	  is	  invited	  to	  participate	  in	  a	  study	  being	  run	  as	  a	  student	  Master’s	  Thesis	  that	  will	  evaluate	  
a	  nutritional	  supplement	  in	  the	  treatment	  of	  anxiety.	  There	  is	  much	  interest	  lately	  in	  complementary	  
alternative	  medicines	  (CAM)	  to	  problems	  such	  as	  those	  your	  child	   is	  experiencing.	  The	  supplement	  
we	   are	   studying	   has	   shown	   some	   promise	   in	   the	   treatment	   of	  mood	   instability	   and	   symptoms	   of	  
anxiety,	  as	  shown	  in	  an	  open-­‐label	  trial	  with	  adults	  experiencing	  stress	  conducted	  at	  the	  University	  
of	   Canterbury.	   The	   supplement	   is	   called	  EMPowerplus	   (EMP+)	   and	   it	   contains	   36	  micronutrients.	  
Your	   child	   is	   eligible	   for	   this	   study	  because	  he/she	   is	   struggling	  with	   anxiety	   and	   stress	   and	   is	   not	  
presently	  on	  psychiatric	  medications.	  Approximately	  15	  children	  in	  Christchurch	  are	  being	  invited	  to	  
take	  part	  in	  this	  study.	  	  
 
Background	  
It	   has	  been	  proposed	   that	   some	  vitamins	   and	  minerals	  might	  help	  people	  with	   anxiety	   and	  mood	  
instability	  to	  improve	  symptoms	  and	  stabilize	  	  mood.	  When	  a	  new	  idea	  such	  as	  this	  comes	  along,	  it	  
must	  be	  studied	   in	  a	  variety	  of	  people	   (referred	   to	  as	  case	  series).	  The	  case	  series	   that	  have	  been	  
carried	  out	  in	  adults	  on	  EMP+	  suggest	  that	  it	  might	  help	  to	  stabilize	  mood	  and	  help	  with	  symptoms	  
of	  anxiety.	  Your	  child	  is	  now	  being	  invited	  to	  participate	  in	  a	  series	  of	  child	  case	  studies	  using	  EMP+.	  	  
 
What	  would	  I	  have	  to	  do?	  
First	   your	   child	   will	   be	   assessed	   for	   eligibility.	   This	   will	   involve	   an	   interview	   with	   you	   and	   other	  
members	  of	  your	  child’s	   family	  to	  ask	  about	  difficulties	  your	  child	   is	  experiencing.	  We	  will	  also	  ask	  
you	  to	  complete	  some	  questionnaires	  about	  your	  child.	  If	  your	  child	  is	  eligible	  we	  will	  then	  proceed	  
with	   the	   intervention	   phase.	   Your	   child	   will	   be	   randomised	   to	   one	   of	   three	   groups,	   each	   with	   a	  
different	  start	  date	  and	  may	  need	  to	  wait	  until	  all	  15	  participants	  are	  recruited.	  This	  is	  a	  study	  design	  
called	  multiple-­‐baseline.	  This	  design	  allows	  us	   to	   see	   if	   changes	   in	   symptoms	  correspond	  with	   the	  
period	   immediately	   after	   the	   intervention	   is	   given.	   This	   provides	   further	   evidence	   that	   it	   is	   the	  
intervention	   which	   is	   improving	   symptoms	   rather	   than	   something	   else.	   Each	   group	   will	   start	   the	  
intervention	  one	  week	  apart.	  	  
	  




The	   preferred	   method	   for	   administration	   of	   the	   intervention	   is	   to	   have	   your	   child	   swallow	   the	  
micronutrient	   formula	   in	   pill	   form.	   However,	   if	   this	   becomes	   too	   difficult	   for	   your	   child,	   the	  
micronutrient	  formula	  is	  available	  in	  powdered	  form	  that	  could	  be	  incorporated	  into	  a	  smoothie	  or	  
milkshake	   just	   prior	   to	   him/her	   taking	   it.	   It	   is	   up	   to	   your	   child	   how	   best	   to	   take	   the	   supplement.	  
Before	  your	  child	  begins	  taking	  the	  capsules	  he/she	  will	  be	  shown	  a	  short	  video	  on	  different	  ways	  to	  
swallow	   capsules.	   He/she	  will	   then	   practice	   swallowing	   by	   using	   hard	   lollies	   and	   recording	  which	  
ways	   he/she	   prefers	   to	   have	   his/her	   head	   when	   swallowing.	   We	   will	   ask	   him/she	   to	   monitor	  
preferred	  head	  positions	  over	  a	  number	  of	  days.	  
	  
Once	  your	  child	   is	   ready	   to	  begin,	  your	  child	  will	   take	  8	  gelatin	  capsules	  per	  day,	  divided	  however	  
you	   like,	   but	   preferably	   in	   2	   doses.	   Your	   child	  will	   begin	   by	   taking	   4	   capsules	   of	   EMP+	   each	   day,	  
increasing	  to	  8	  capsules	  on	  the	  4th	  day.	  Attached	  to	  this	  consent	  form	  is	  a	  list	  of	  all	  the	  ingredients	  in	  
EMP+.	  It	  will	  be	  important	  for	  your	  child	  to	  drink	  plenty	  of	  water	  every	  day	  to	  properly	  absorb	  these	  
ingredients.	  Your	  child	  will	  take	  the	  supplement	  for	  8	  weeks.	  You	  will	  be	  responsible	  for	  making	  sure	  
that	   your	   child	   takes	   the	   appropriate	   amount	   of	   supplement,	   as	   well	   as	   making	   sure	   that	   the	  
supplements	  are	  not	  shared	  with	  others.	  	  
	  
During	  the	  entire	  trial,	  which	  will	  be	  approximately	  2-­‐3	  months,	  there	  will	  be	  weekly	  or	  fortnightly	  
appointments	  with	  one	  of	  the	  primary	   investigators.	  At	  your	  appointments,	  this	  person	  will	  review	  
the	  physical	  and	  mental	  health	  of	  your	  child,	  will	  ask	  about	  any	  problems	  he/she	  is	  having,	  and	  will	  
complete	   a	   number	   of	   assessment	   tools	   evaluating	   his/her	   overall	   functioning.	   At	   every	  
appointment,	   we	  will	   also	   ask	   you	   to	   complete	   questionnaires	   about	   your	   child	   regarding	   overall	  
level	  of	  functioning.	  Your	  child	  will	  be	  asked	  to	  record	  in	  a	  daily	  diary	  how	  he/she	  is	  feeling	  each	  day	  
and	  how	  much	  he/she	  worried	   that	   day.	   This	  will	   involve	   circling	   the	   appropriate	  picture	   for	   how	  
he/she	  feels.	  You	  will	  also	  be	  asked	  to	  record	  here	  any	  unusual	  events	   in	  your	  child’s	   life,	  and	  any	  
capsules	  that	  you	  know	  have	  not	  been	  taken.	  	  
	  
In	   addition	   to	   the	   above	   questionnaires,	  we	  will	   also	  measure	   cortisol.	   Cortisol	   is	   a	   hormone	   the	  
body	  produces	   in	   response	   to	   stress	  and	  anxiety.	  Cortisol	   levels	  are	  higher	   in	  people	  with	  a	   lot	  of	  
stress	  or	  anxiety.	  We	  will	  measure	  cortisol	  to	  determine	  if	  the	  supplement	  helps	  reduce	  your	  child’s	  
response	   to	   stress.	   We	   can	   measure	   cortisol	   in	   saliva.	   Your	   child	   will	   provide	   a	   total	   of	   8	   saliva	  
samples.	   This	   procedure	   is	   easy	   and	   non-­‐invasive.	   Children	   will	   use	   a	   method	   where	   they	   direct	  
saliva	   through	   a	   straw	   into	   a	   tube.	   This	   method	   is	   called	   passive	   drooling.	   We	   need	   to	   collect	  
samples	  over	  two	  consecutive	  days,	  in	  the	  morning	  before	  breakfast	  and	  evening	  before	  tea,	  both	  at	  
the	  start	  and	  end	  of	  the	  trial.	  
	  
Overall,	  the	  approximate	  time	  involved	  for	  initial	  interview	  and	  baseline	  assessment	  will	  be	  around	  
two	  to	  three	  hours	  over	  two	  visits	  There	  will	  be	  four	  to	  six	  hours	  for	  visits	  weekly	  or	  fortnightly	  to	  
the	   University	   of	   Canterbury	   including	   completion	   of	   questionnaires	   by	   you	   and	   your	   child	   plus	  
around	  15	  minutes	  for	  a	  follow-­‐up	  call	  at	  week	  1	  and	  about	  one	  hour	  at	  three	  month	  follow	  up	  for	  a	  
phone	   interview	   and	   completion	   of	   questionnaires.	   Daily	   your	   child	  will	   be	   expected	   to	   complete	  
his/her	  feelings	  diary.	  This	  will	  take	  them	  less	  than	  five	  minutes.	  Each	  saliva	  sample	  will	  take	  five	  to	  
ten	  minutes	  to	  collect,	  totally	  approximately	  one	  and	  one	  half	  hours	  over	  four	  days.	  A	  schedule	  can	  
be	   found	   below	   detailing	   the	   order	   of	   assessment	   and	   visit	   time.	   Visits	   will	   take	   less	   time	   if	  
questionnaires	  can	  be	  done	  at	  home	  beforehand	  and	  brought	  along.	  
	  
If	  an	  antibiotic	  or	  antifungal	  agent	  must	  be	  taken	  orally	  for	  a	  health	  problem,	  it	  may	  be	  necessary	  for	  
you	  to	  withdraw	  your	  child	  from	  the	  study	  for	  the	  time	  he/she	  needs	  to	  complete	  the	  course	  of	  the	  
drug.	   If	   it	   is	   appropriate	   for	   your	   child	   to	   continue	   taking	   EMP+	  while	   taking	   one	   of	   these	   agents	  
he/she	  will	  be	  monitored	  closely.	  This	  is	  because	  antibiotics	  and	  antifungal	  drugs	  seem	  to	  interfere	  
with	  the	  absorption	  of	  this	  nutrient	  supplement.	  





You	  will	  be	  asked	  to	  not	  have	  your	  child	  try	  any	  alternative	  medicines	  or	  other	  forms	  of	  therapy	  until	  
he/she	  has	  completed	  his/her	  involvement	  in	  this	  study.	  	  
	  
Members	  of	  all	  cultures	  will	  be	  encouraged	  to	  participate	   in	  the	  study.	  Respect	   for	  Maori	  customs	  
and	  traditions	  are	  of	  the	  highest	  priority	  and	  if	  necessary,	  home	  visits	  with	  a	  cultural	  advisor	  can	  be	  
conducted.	   The	   researchers	   are	   available	   to	   discuss	   the	   research	   with	   the	   whanau	   to	   assist	   in	  
developing	  their	  understanding	  of	  the	  clinical	  disorders	  and	  how	  the	  disorders	  can	  impact	  on	  te	  taha	  
hinengaro	   (mental	   wellbeing),	   whanaungatanga	   (family	   relationships),	   taha	   wairua	   (spiritual	  
wellbeing)	  and	  taha	  tinana	  (physical	  wellbeing).	  
	  
Table	  1.1	  Schedule	  of	  Assessment	  
	  
Assessment	  Number	   Assessment	  Type	   Time	  Involved	  
Initial	  interview	   Initial	   visit	   for	   assessment	   and	   pill	   swallowing	  
training.	  Also	  given	  saliva	  sample	  collection	  kit	  with	  
samples	   to	   be	   collected	   during	   the	   week	   before	  
baseline	  assessment.	  
1.5	  –	  2	  hours	  and	  40	  minutes	  
over	   2	   days	   for	   saliva	  
collection	  
Baseline	   Completion	   of	   questionnaires	   and	   given	  
micronutrients	  
1.5	  –	  2	  hours	  
Week	  1	   Phone	  follow-­‐up	   15	  	  minutes	  
Week	  2	   Visit	  for	  fortnightly	  monitoring	   1	  hour	  
Week	  3	   	   	  
Week	  4	   Visit	  for	  fortnightly	  monitoring	   1	  hour	  
Week	  5	   	   	  
Week	  6	   Visit	  for	  fortnightly	  monitoring	   1	  hour	  
Week	  7	   	   	  
Week	  8	   Final	   visit	   and	   completion	   of	   study.	   During	   this	  
week	  saliva	  samples	  will	  also	  be	  collected.	  	  
1	   hour	   and	   40	  minutes	   over	  
2	  days	  for	  saliva	  collection	  





What	  are	  the	  risks?	  
	  
Although	   we	   have	   no	   reason	   to	   suspect	   that	   this	   supplement	   can	   harm	   a	   physically	   healthy	  
individual	   in	   any	  way,	  we	  will	  monitor	   your	   child	   regularly.	   You	  will	  meet	   or	   have	   phone	   contact	  
every	   other	  week	  with	   one	   of	   the	   investigators	  who	  will	   ask	   questions	   about	   your	   child’s	   general	  
physical	  and	  mental	  health	  and	  wellbeing.	  	  
	  
In	   previous	   research	   at	   the	  University	   of	   Calgary	   in	   Canada,	   blood	   samples,	   heart	   rate,	   and	  blood	  
pressure	  were	  monitored	   in	  12	  children,	  and	  no	  one	  was	   found	  to	  experience	  any	  problems	  while	  
taking	   the	   supplement.	   This	   type	   of	   supplement	   has	   been	   used	   by	   many	   people	   for	   many	   years	  
without	  any	  unpleasant	  results	   reported.	   	  More	  recently,	  27	  adults	  with	  bipolar	  disorder	  had	  their	  
blood	  tested	  to	  determine	  whether	  they	  were	  all	   fine	  after	  taking	  Empowerplus	  for	  1-­‐3	  years,	  and	  
there	  were	  no	  health	  concerns	  in	  those	  test	  results	  that	  were	  attributable	  to	  the	  supplement.	  There	  




were	  some	  findings	  which	  the	  reviewing	  physician	  considered	  to	  be	  "incidental,"	  but	  not	  attributable	  
to	   any	   adverse	   effects	   of	   the	   supplement.	   In	   our	   trials	   conducted	   here	   at	   Canterbury,	   we	   have	  
assessed	  to	  date	  76	  patients	  before	  taking	  EMP+	  and	  8	  to	  16	  weeks	  after.	  There	  were	  no	  abnormal	  
blood	  results	  that	  suggested	  that	  EMP+	  was	  having	  an	  adverse	  effect	  on	   liver	  and	  kidney	  function.	  
Further,	  any	  side	  effects	  reported	  by	  this	  sample	  were	  temporary	  and	  mild.	  Further,	  the	  dose	  we	  are	  
using	  is	  half	  the	  dose	  used	  in	  our	  other	  trials	  which	  further	  reduces	  the	  chance	  of	  adverse	  effects.	  
	  
Some	   of	   the	   ingredients	   in	   EMP+	   are	   given	   at	   amounts	   higher	   than	   the	   recommended	   daily	  
allowance	  (RDA)	  for	  that	  nutrient.	  This	  is	  because	  there	  is	  research	  suggesting	  that	  some	  people	  may	  
need	  more	  than	  the	  daily	  allowance	  for	  optimal	  brain	  functioning.	  Although	  the	  doses	  are	  high,	  they	  
are	   not	   being	   given	   in	   a	   level	   that	   is	   believed	   to	   be	   toxic	   to	   the	   system.	   Indeed,	   by	   consuming	  
nutrients	   in	  combination,	  risks	  of	  toxicity	  are	  decreased.	  We	  will	  monitor	  your	  child	  closely	  for	  any	  
sign	  of	  toxicity.	  
	  
The	  most	  common	  ‘side	  effects’	  are	  that	  previously-­‐experienced	  constipation	  has	  been	  relieved	  and	  
that	  the	  patient	  is	  sleeping	  better;	  i.e.,	  positive	  side	  effects	  rather	  than	  adverse	  events.	  	  The	  patients	  
who	  have	  stopped	  EMP+	  have	  most	  commonly	  done	  so	  because	  of	  the	  indigestion	  type	  symptoms	  or	  
due	  to	  problems	  with	  interactions	  with	  other	  medications	  (see	  below).	  Some	  of	  these	  difficulties	  can	  
be	  avoided	  by	  taking	  the	  capsules	  on	  a	  full	  stomach,	  and	  so	  we	  suggest	  your	  child	  always	  take	  their	  
capsules	   with	   food.	   	  Another	   way	   to	   prevent	   these	   side	   effects	   is	   increase	   the	   dose	   slowly	   over	  
several	  days,	  so	  we	  begin	  with	  four	  capsules	  per	  day	  and	  increase	  gradually	  to	  the	  full	  dose.	  We	  will	  
review	  side-­‐effects	  with	  you	  and	  your	  child	  at	  each	  visit	  and	  make	  a	  referral	  to	  a	  medical	  practitioner	  
if	  necessary.	  We	  are	  happy	  to	  provide	  you	  with	  copies	  of	  the	  studies	  that	  have	  been	  done	  to	  date	  on	  
EMP+.	  
	  	  
EMP+	  has	   the	  potential	   to	   interact	  with	  other	  medicines	  or	  drugs	   so	   if	   possible,	   you	   should	  avoid	  
having	   your	   child	   take	   other	   medicines	   whilst	   on	   this	   treatment.	   For	   this	   reason,	   we	   are	   only	  
including	  individuals	  in	  the	  study	  who	  are	  not	  being	  concurrently	  treated	  using	  prescribed	  psychiatric	  
medications.	  With	   respect	   to	  whether	  your	  child	   should	   take	  other	  medications,	   such	  as	  over-­‐the-­‐
counter	   medications	   to	   treat	   colds,	   flu,	   stomach	   upset	   and	   sleep	   problems,	   because	   they	   may	  
interact	  with	  EMP+,	  you	  should	  first	  discuss	  with	  us	  or	  your	  pharmacist	  before	  use.	  Pain	  killers	  such	  
as	  Aspirin,	  Nurofen,	  Brufen	  or	  Voltaren	  (the	  NSAIDs	  or	  non-­‐steroidal	  anti-­‐inflammatory	  drugs)	  should	  
be	   avoided	   whilst	   on	   EMP+	   as	   they	   can	   affect	   the	   ability	   of	   your	   blood	   to	   clot,	   and	   hence	   stop	  
bleeding	   from	  a	  cut,	   in	  a	  similar	  way	   to	  some	  of	   the	   ingredients	  of	  EMP+.	  So,	   for	  example,	   if	  your	  
child	   needed	   a	   pain	   killer	   for	   a	   headache,	   it	   would	   be	   safer	   for	   him/her	   to	   take	   Paracetamol	   or	  
Panadol	  than	  Nurofen	  whilst	  on	  EMP+.	  	  A	  list	  of	  appropriate	  medications	  that	  are	  acceptable	  to	  take	  
during	  this	  trial	  is	  included	  as	  part	  of	  this	  information	  sheet.	  	  
	  
Your	  child’s	  safety	  is	  the	  most	  important	  thing.	  Thus,	  in	  the	  event	  of	  an	  emergency	  (e.g.,	  if	  your	  child	  
has	   thoughts	  of	  harming	   themself	  or	  others),	   you	  should	   take	  your	  child	   to	  psychiatric	  emergency	  
services.	   The	   emergency	   room	   personnel	   can	   call	   the	   number	   on	   your	   pill	   bottle	   to	   obtain	  
information	   about	   the	   study	   and	   about	   the	   contents	   of	   the	   capsules	   your	   child	   is	   taking.	   The	  
contents	  are	  also	  listed	  at	  the	  end	  of	  this	  information	  sheet.	  
	  
If	  my	  child	  suffers	  a	  research-­‐related	  injury,	  will	  I	  be	  compensated?	  
In	  the	  unlikely	  event	  of	  a	  physical	  injury	  as	  a	  result	  of	  your	  child’s	  participation	  in	  this	  study,	  he/she	  
may	   be	   covered	   by	   ACC	   under	   the	   Injury	   Prevention,	   Rehabilitation	   and	   Compensation	   Act.	   	   ACC	  
cover	  is	  not	  automatic	  and	  your	  case	  will	  need	  to	  be	  assessed	  by	  ACC	  according	  to	  the	  provisions	  of	  
the	  2001	  Injury	  Prevention	  Rehabilitation	  and	  Compensation	  Act.	  	  If	  your	  claim	  is	  accepted	  by	  ACC,	  
you	  still	  might	  not	  get	  any	  compensation.	  	  This	  depends	  on	  a	  number	  of	  factors	  such	  as	  whether	  you	  
are	  an	  earner	  or	  non-­‐earner.	  	  ACC	  usually	  provides	  only	  partial	  reimbursement	  of	  costs	  and	  expenses	  




and	  there	  may	  be	  no	  lump	  sum	  compensation	  payable.	  	  There	  is	  no	  cover	  for	  mental	  injury	  unless	  it	  
is	  a	   result	  of	  physical	   injury.	   	   If	  you	  have	  ACC	  cover,	  generally	   this	  will	  affect	  your	  right	   to	  sue	  the	  
investigators.	   If	   you	   have	   any	   questions	   about	   ACC,	   contact	   your	   nearest	   ACC	   office	   or	   the	  
investigator.	  
	  
Will	  my	  child	  benefit	  if	  they	  take	  part?	  
There	  may	  or	  may	  not	  be	  a	  direct	  medical	  benefit	  to	  your	  child.	  His/her	  symptoms	  may	  be	  improved	  
during	   the	   study	  but	   there	   is	   no	   guarantee	   that	   this	   research	  will	   help	   them.	   The	   information	  we	  
obtain	  from	  this	  study	  may	  help	  us	  to	  provide	  better	  treatments	   in	  the	  future	  for	  people	  suffering	  
from	  stress	  or	  anxiety.	  
	  
Does	  my	  child	  have	  to	  participate?	  
If	  you	  or	  your	  child	  decide	  not	  to	  participate	  in	  this	  study,	  or	  if	  you	  decide	  part-­‐way	  through	  that	  you	  
want	  him/her	  to	  stop,	  you	  are	  certainly	  free	  to	  do	  so.	  This	  decision	  will	  not	  influence	  his/her	  ongoing	  
health	   care	   in	   any	   way.	   Similarly,	   the	   study’s	   investigators	   might	   choose	   to	   end	   your	   child’s	  
participation	  in	  the	  study	  at	  any	  time	  for	  any	  reason,	  for	  instance	  if	  we	  are	  concerned	  about	  safety.	  If	  
new	  information	  becomes	  available	  that	  might	  affect	  your	  willingness	  to	  have	  your	  child	  participate	  
in	  the	  study,	  you	  will	  be	  informed	  as	  soon	  as	  possible.	  There	  are	  many	  other	  treatments	  available	  for	  
anxiety,	   including	   cognitive-­‐behavioural	   and	   behavioural	   therapy	   and	   in	   severe	   cases,	  medication.	  
We	   are	   happy	   to	   assist	   you	   with	   finding	   help	   if	   you	   would	   rather	   choose	   these	   evidence	   based	  
treatments.	  You	  may	  also	  choose	  to	  go	  this	  route	  at	  the	  end	  of	  the	  trial	  and	  again,	  we	  will	  assist	  you	  
in	  finding	  the	  services	  available	  in	  Christchurch.	  	  
	  
Will	  I	  be	  paid	  for	  my	  child’s	  participation,	  or	  do	  I	  have	  to	  pay	  for	  anything?	  
Arrangements	  will	  be	  made	  with	  each	  individual	  participant	  to	  ensure	  that	  your	  transportation	  costs	  
are	  covered.	  At	  each	  visit,	  you	  will	   receive	  a	  petrol	  voucher	   to	  cover	  costs.	  The	  capsules	   that	  your	  
child	  will	  take	  during	  the	  study	  will	  be	  provided	  at	  no	  cost.	  	  
	  
Will	  my	  child’s	  records	  be	  kept	  private?	  
All	  information	  about	  your	  child	  that	  is	  collected	  in	  this	  study	  will	  be	  held	  in	  the	  strictest	  confidence.	  
The	  only	  people	  who	  will	  have	  access	  to	  the	  information	  are	  the	  study	  investigators	  and	  designated	  
staff.	   We	   are	   very	   careful	   in	   dealing	   with	   confidential	   information;	   you	   can	   feel	   assured	   that	   all	  
information	   you	   disclose	   concerning	   your	   child	   and	   your	   family	   will	   be	   kept	   in	   a	   confidential	   file	  
which	  will	  be	  kept	  locked	  at	  all	  times.	  	  This	  data	  will	  be	  stored	  for	  10	  years	  after	  collection.	  With	  your	  
permission,	   data	   from	   this	   study	   may	   be	   used	   in	   future	   related	   studies,	   which	   have	   been	   given	  
ethical	  approval	  from	  a	  Health	  and	  Disability	  Ethics	  Committee.	  All	  information	  will	  be	  kept	  as	  group	  
data.	   	   Therefore,	   forms	   will	   be	   coded	   and	   names	   removed	   such	   that	   you	   cannot	   be	   identified.	  
Confidentiality	  will	  be	  respected	  and	  no	  material	  which	  could	  personally	  identify	  your	  child	  or	  family	  
will	   be	   used	   in	   any	   reports	   on	   this	   study.	  However,	   in	   cases	  where	  we	   are	   concerned	   about	   your	  
safety	  or	  the	  safety	  of	  others,	  we	  may	  decide	  to	  breach	  confidentiality.	  	  	  
	  
The	  results	  of	  the	  tests	  described	  above	  will	  be	  used	  for	  research	  purposes	  only	  in	  the	  context	  of	  this	  
study.	   	  We	  would	  need	   your	   permission	   and	   signed	   consent	   to	   send	   these	   test	   scores	   to	   another	  
professional	  involved	  in	  your	  child’s	  care.	  	  We	  recommend	  that	  a	  psychologist	  or	  physician	  interpret	  
the	  results	  of	  these	  tests.	  During	  this	  study,	  it	  may	  be	  necessary	  for	  a	  member	  of	  the	  research	  team	  




What	  happens	  after	  the	  study?	  




If	   you	   feel	   your	   child	  has	  benefited	  at	   the	  end	  of	   the	   trial,	   and	  want	   them	   to	   continue	   taking	   the	  
supplement,	   it	   is	  commercially	  available.	  We	  can	  provide	  you	  with	  the	  contact	   information	  so	  that	  
you	  can	  continue	  to	  obtain	  it.	  	  
	  
If	   you	   have	   any	   queries	   or	   concerns	   regarding	   your	   rights	   as	   a	   participant	   in	   the	   study	   you	   can	  
contact	   an	   independent	   health	   and	   disability	   advocate.	   This	   is	   a	   free	   service	   provided	   under	   the	  
Health	   and	  Disability	   Commissioner	   Act.	   Telephone	   (NZ	  Wide)	   0800	   555	   050,	   Free	   Fax	   (NZ	  wide):	  
0800	  2787	  7678	  (0800	  2	  SUPPORT),	  Email	  (NZ	  wide)	  advocacy@hdc.org.nz.	  You	  can	  also	  contact	  Dr.	  
Julia	   Rucklidge,	   the	   principal	   investigator,	   364-­‐2987	   ext7959,	   should	   you	   have	   any	   questions	   or	  
concerns	  about	  this	  research.	  The	  Human	  Ethics	  committee	  at	  the	  University	  of	  Canterbury	  and	  the	  
Upper	   South	   A	   Regional	   Ethics	   Committee	   have	   reviewed	   and	   approved	   this	   study.	  We	   have	   also	  
consulted	  with	  The	  Maori	  Consultation	  Group	  at	  the	  University	  of	  Canterbury.	  
	  
University	  of	  Canterbury	  Human	  Ethics	  Committee	  
Chair: Dr Mike Grimshaw  
Telephone: 6390 or +64 3 364 2390 
michael.grimshaw@canterbury.ac.nz











PARENTAL	  CONSENT	  FORM	  
 
 
Title	  of	  research	  project:	  	  A	  pilot	  investigation	  into	  the	  effect	  of	  micronutrients	  on	  anxiety	  and	  stress	  
in	  Canterbury	  children:	  a	  multiple	  baseline	  design	  	  
	  
Principal Investigators: Assoc Prof Julia Rucklidge, Ellen Sole, Assoc Prof Neville 
Blampied  
	  
I	  have	  read	  and	  I	  understand	  the	  information	  sheet	  dated	  April	  26th	  2012	  for	  people	  taking	  part	  in	  
the	  study	  designed	  to	  assess	  the	  impact	  of	  micronutrients	  on	  anxiety	  and	  mood	  in	  children	  with	  
elevated	  anxiety.	  	  I	  have	  had	  the	  opportunity	  to	  discuss	  this	  study.	  	  I	  am	  satisfied	  with	  the	  answers	  I	  
have	  been	  given.	  
	  
I	  believe	  that	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  
	  (participant’s	  name)	  would	  have	  chosen	  and	  
consented	  to	  participate	  in	  this	  study	  if	  he/she	  had	  been	  able	  to	  understand	  the	  information	  that	  I	  
have	  received	  and	  understood.	  
	  
I	  understand	  that	  taking	  part	  in	  this	  study	  is	  voluntary	  and	  that	  my	  child	  may	  withdraw	  from	  the	  
study	  at	  any	  time	  if	  he/she	  wishes.	  	  This	  will	  not	  affect	  his/her	  continuing	  health	  care.	  
	  
I	  understand	  that	  his/her	  participation	  in	  this	  study	  is	  confidential	  and	  that	  no	  material	  which	  could	  
identify	  him/her	  will	  be	  used	  in	  any	  reports	  on	  this	  study.	  
	  
I	  understand	  that	  the	  treatment	  will	  be	  stopped	  if	  it	  should	  appear	  to	  be	  harmful.	  
	  
I	  understand	  the	  compensation	  provisions	  for	  this	  study.	  
	  
I	  know	  whom	  to	  contact	  if	  my	  child	  has	  any	  side	  effects	  to	  the	  study	  or	  if	  anything	  occurs	  which	  I	  
think	  he/she	  would	  consider	  a	  reason	  to	  withdraw	  from	  the	  study.	  
	  
I	  understand	  that	  I	  can	  request	  for	  a	  karakia	  at	  the	  point	  of	  disposal	  of	  my	  child’s	  tissue	  samples.	  	  	  
	  
I	  know	  whom	  to	  contact	  if	  I	  have	  any	  questions	  about	  the	  supplement	  of	  the	  study.	  
	  
This	  study	  has	  been	  given	  ethical	  approval	  by	  the	  both	  the	  Human	  and	  Disabilities	  Ethics	  Committee	  
and	  the	  Human	  Ethics	  Committee	  at	  the	  University	  of	  Canterbury.	  	  This	  means	  that	  the	  Committee	  
may	  check	  at	  any	  time	  that	  the	  study	  is	  following	  appropriate	  ethical	  procedures.	  
	  
I	  consent	  to	  my	  child	  supplying	  saliva	  samples	  as	  indicated	  and	  to	  these	  samples	  being	  used	  to	  
analyse	  cortisol	  level	   	   	   	   	   YES/NO	  
	  




I	  agree	  to	  my	  GP	  or	  other	  current	  provider	  being	  informed	  of	  my	  child’s	  participation	  in	  this	  
study/the	  results	  of	  my	  child’s	  participation	  in	  this	  study	  and	  be	  provided	  with	  any	  laboratory	  
reports	  obtained	  for	  the	  purposes	  of	  this	  study	   	   	   YES/NO	  
	  
I	  consent	  to	  being	  contacted	  approximately	  8	  weeks	  following	  the	  initial	  assessment	  for	  a	  review	  
regardless	  of	  whether	  my	  child	  continued	  with	  the	  treatment.	  I	  understand	  we	  do	  not	  have	  to	  
complete	  the	  assessment	  at	  that	  time.	  	   	   	   	   YES/NO	  
	  
I	  consent	  to	  my	  child’s	  name	  being	  placed	  in	  a	  separate	  database	  so	  that	  I	  can	  be	  contacted	  in	  the	  
future	  should	  there	  be	  other	  studies	  for	  them	  to	  participate	  in	  with	  the	  understanding	  that	  I	  can	  
choose	  whether	  they	  participate	  in	  such	  studies	  or	  not.	  
	   	   	   	   	   	   	   YES/NO	  
	  
I	  consent	  to	  the	  use	  of	  my	  child’s	  data	  for	  future	  related	  studies,	  which	  have	  been	  given	  ethical	  
approval	  from	  a	  Health	  and	  Disability	  Ethics	  Committee	   	   	   YES/NO	   	  
	  
We	  would	  like	  a	  copy	  of	  the	  results	  of	  the	  study.	  	  	   	   	  	  	  	  	   YES/NO	  
 
Participants should be advised that a significant delay may occur between data collection and 
publication of the results.   
 
	  
Signed:  Date:  
  
Printed name:  
  
Relationship to participant:  
  
Address for results:  
	  
The	  person	  who	  may	  be	  contacted	  about	  the	  research	  is:	  
	  
	  Dr.	  Julia	  Rucklidge,	  Principal	  Investigator,	  364-­‐2987	  ext	  7959	  
	  
	  
A	  signed	  copy	  of	  this	  consent	  form	  has	  been	  given	  to	  you	  to	  keep	  for	  your	  records	  and	  reference.	  	  
	  
Ingredients	  of	  EMP+	  attached.	  
	   	  




EMPowerplus	  Capsule	  Ingredient	  List	  (Current)	  
	  
1	  cap	   4	  caps	   8	  caps	   	  
384.0	   IU	   1536.0	   IU	   3072.0	   IU	   Vitamin	  A	  	  
40.0	   mg	   160.0	   mg	   320.0	   mg	   Vitamin	  C	  	  
96.0	   IU	   384.0	   IU	   768.0	   IU	   Vitamin	  D	  	  
24.0	   IU	   96.0	   IU	   192.0	   IU	   Vitamin	  E	  	  	  
1.2	   mg	   4.8	   mg	   9.6	   mg	   Vitamin	  B1	  	  
0.9	   mg	   3.6	   mg	   7.2	   mg	   Vitamin	  B2	  	  
6.0	   mg	   24.0	   mg	   48.0	   mg	   Vitamin	  B3	  	  
1.4	   mg	   5.8	   mg	   11.5	   mg	   Vitamin	  B5	  	  
2.4	   mg	   9.6	   mg	   19.2	   mg	   Vitamin	  B6	  	  
96.0	   ug	   384.0	   ug	   768.0	   ug	   Vitamin	  B9	  	  
60.0	   ug	   240.0	   ug	   480.0	   ug	   Vitamin	  B12	  	  
72.0	   ug	   288.0	   ug	   576.0	   ug	   Vitamin	  H	  	  
88.0	   mg	   352.0	   mg	   704.0	   mg	   Calcium	  	  
0.9	   mg	   3.7	   mg	   7.3	   mg	   Iron	  	  
56.0	   mg	   224.0	   mg	   448.0	   mg	   Phosphorus	  
13.6	   ug	   54.4	   ug	   108.8	   ug	   Iodine	  	  
40.0	   mg	   160.0	   mg	   320.0	   mg	   Magnesium	  
3.2	   mg	   12.8	   mg	   25.6	   mg	   Zinc	  
13.6	   ug	   54.4	   ug	   108.8	   ug	   Selenium	  
0.5	   mg	   1.9	   mg	   3.8	   mg	   Copper	  
0.6	   mg	   2.6	   mg	   5.1	   mg	   Managnese	  
41.6	   ug	   166.4	   ug	   332.8	   ug	   Chromium	  	  
9.6	   ug	   38.4	   ug	   76.8	   ug	   Molybdenum	  	  
16.0	   mg	   64.0	   mg	   128.0	   mg	   Potassium	  
24.0	   mg	   96.0	   mg	   192.0	   mg	   dl-­‐phenylalanine	  
12.0	   mg	   48.0	   mg	   96.0	   mg	   glutamine	  
16.0	   mg	   64.0	   mg	   128.0	   mg	   citrus	  bioflavanoids	  
3.0	   mg	   12.0	   mg	   24.0	   mg	   grape	  seed	  
36.0	   mg	   144.0	   mg	   288.0	   mg	   choline	  bitartrate	  
12.0	   mg	   48.0	   mg	   96.0	   mg	   Inositol	  
2.4	   mg	   9.6	   mg	   19.2	   mg	   ginkgo	  biloba	  
4.0	   mg	   16.0	   mg	   32.0	   mg	   methionine	  
1.4	   mg	   5.5	   mg	   11.0	   mg	   Germanium	  sesquioxide	  
160.0	   ug	   640.0	   ug	   1280.0	   ug	   Boron	  
2.0	   ug	   7.8	   ug	   15.7	   ug	   Nickel	  
79.6	   ug	   318.4	   ug	   636.8	   ug	   vanadium	  
	  	   	  	   	  	   	  	   	  	   	  	   	  	  
111.0	   	   444.1	   	   888.2	   	   Proprietary	  Total	  
	  
	  









Medication Management Information for the Study Participants 
 
As you know from the intensive screening you went through prior to your child being 
invited to participate in this study, it is very important that participants avoid anything 
with known effects on the brain (alcohol, street drugs, and many medications). The 
following information will help guide you if your child develops a problem during the 
trial, such as a head cold. 
 
Herbals,	  etc	  
Echinacea,	  chrondroitin,	  and	  glucosamine	  are	  permitted	  with	  no	  restrictions	  on	  dose	  changes.	  	  
 
Over-the counter medications 
• If	  your	  child	  has	  trouble	  with	  nausea,	  please	  remember	  to	  take	  capsules	  with	  food.	  Please	  
talk	  to	  the	  research	  clinician	  if	  this	  problem	  persists	  
	   	  
• If	  your	  child	  has	  diarrhoea,	  please	  talk	  to	  the	  research	  clinician.	  
	  	  
• If	  your	  child	  needs	  help	  with	  some	  type	  of	  pain,	  the	  preferred	  treatment	  is	  paracetamol	  	  
	  
• If	  your	  child	  gets	  a	  cold,	  you	  may	  treat	  their	  cough	  with	  something	  like	  guaifensin	  (Plain	  




	   	  













































What is a Research Study? A research study is when someone collects a lot of 
information to learn more about something. You are being asked to be in this research 
study because we are trying to learn more about anxiety. There will be about 14 other 
children in the study. 
If	  you	  join	  the	  study	  what	  will	  you	  
have	  to	  do?	  
	  
-­‐ You	  will	  visit	  the	  university	  for	  
activities	  and	  questions	  every	  
second	  week	  for	  about	  3	  months.	  
-­‐ You	  will	  take	  some	  vitamins	  and	  
minerals	  every	  day	  for	  2	  months	  
and	  fill	  out	  a	  daily	  feelings	  diary.	  
-­‐ You	  can	  choose	  to	  take	  the	  
vitamins	  and	  minerals	  as	  pills	  or	  a	  
powder	  to	  mix	  into	  a	  drink.	  
-­‐ You	  will	  need	  to	  give	  a	  small	  
amount	  of	  saliva	  8	  times	  
throughout	  the	  study.	  
Will	  the	  study	  help	  you?	  
	  
-­‐ The	  pills	  in	  this	  study	  have	  helped	  
some	  adults	  with	  anxiety	  and	  
stress	  but	  it	  may	  or	  may	  not	  help	  
you	  
-­‐ We	  don’t	  know	  if	  your	  anxiety	  will	  
get	  better	  because	  you	  take	  part	  
in	  the	  study	  but	  we	  hope	  that	  it	  
does	  
-­‐ This	  study	  may	  find	  out	  things	  that	  
can	  help	  other	  children	  you	  feel	  
like	  you	  
A	  pilot	  study	  investigating	  the	  effect	  of	  micronutrients	  on	  anxiety	  
and	  stress	  in	  children.	  





	   	  
Who	  will	  see	  the	  	  
information	  you	  give	  us?	  
	  
-­‐ only	  people	  working	  on	  
the	  study	  will	  see	  your	  
information	  and	  it	  will	  all	  
be	  kept	  in	  a	  locked	  
cabinet.	  
Will	  any	  part	  of	  the	  study	  hurt?	  
	  
-­‐ The	  vitamins	  and	  minerals	  might	  make	  
upset	  your	  tummy	  or	  give	  you	  a	  sore	  head	  
-­‐ This	  is	  important	  to	  know	  and	  we	  will	  be	  
able	  to	  help	  it	  so	  please	  tell	  your	  parent	  if	  





-­‐ Do	  you	  have	  any	  questions?	  
-­‐ If	  you	  think	  of	  something	  you	  want	  to	  know	  
about	  the	  study	  later	  you	  can	  ring	  us	  or	  get	  
your	  parent	  to	  ring.	  
Do	  you	  have	  to	  be	  in	  the	  study?	  
	  
-­‐ NO.	  And	  nobody	  will	  be	  upset	  if	  don’t	  want	  to	  be	  in	  the	  
study	  
-­‐ If	  you	  want	  to	  be	  part	  of	  the	  research	  study,	  tell	  us	  that	  
-­‐ Remember	  you	  can	  say	  yes	  now	  and	  change	  your	  mind	  
later.	  All	  you	  have	  to	  do	  is	  tell	  the	  person	  in	  charge,	  it	  is	  ok.	  
It	  is	  up	  to	  you!	  




A	  Pilot	  Study	  Investigating	  the	  Effect	  of	  Micronutrients	  on	  	  
Anxiety	  and	  Stress	  in	  Children	  
	  




Sign	  this	  form	  only	  if	  you:	  
	  
• have	  understood	  what	  you	  will	  be	  doing	  for	  this	  study,	  
• have	  had	  all	  your	  questions	  answered,	  
• have	  talked	  to	  your	  parent(s)/legal	  guardian	  about	  this	  project,	  and	  





















Name	  of	  Parent(s)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  
	  















Appendix D: Instruction sheets for taking EMPowerplus in capsule and powder form









Week	  1:	  	  
Day	  1:	  Morning	  (take	  2	  pills),	  Tea	  time	  (take	  2	  pills)	  
Day	  2:	  same	  as	  above	  
Day	  3:	  same	  as	  above	  
Day	  4:	  Morning	  (take	  4	  pills),	  Tea	  time	  (take	  4	  pills)	  
Day	  5:	  same	  as	  above	  
Day	  6:	  same	  as	  above	  
Day	  7:	  same	  as	  above	  
	  
Weeks	  2	  onwards:	  Morning	  (take	  4	  pills),	  Tea	  time	  (take	  4	  pills)	  
	  
• Take	  your	  pills	  with	  food	  and	  one	  large	  glass	  of	  water.	  Drink	  plenty	  of	  water	  during	  the	  day.	  
The	  most	  common	  side	  effect	  of	  taking	  these	  pills	  is	  an	  upset	  stomach.	  This	  can	  be	  avoided	  
by	  taking	  your	  pills	  with	  food	  and	  plenty	  of	  water.	  
	  
• If	  you	  miss	  a	  dose,	  take	  the	  dose	  when	  you	  remember	  but	  make	  sure	  that	  you	  leave	  at	  least	  
2	  hours	  between	  doses.	  
	  
• Try	  not	  to	  take	  your	  last	  dose	  later	  than	  6pm	  because	  sometimes	  the	  pills	  can	  have	  an	  
energising	  effect,	  which	  can	  make	  it	  difficult	  for	  you	  to	  get	  to	  sleep.	  
 









Week	  1:	  	  
Day	  1:	  Morning	  (take	  half	  a	  scoop	  mixed	  with	  liquid),	  Tea	  time	  (take	  half	  a	  scoop	  mixed	  with	  
liquid)	  
Day	  2:	  same	  as	  above	  
Day	  3:	  same	  as	  above	  
Day	  4:	  Morning	  (take	  1	  scoop	  mixed	  with	  liquid),	  Tea	  time	  (take	  1	  scoop	  mixed	  with	  liquid)	  
Day	  5:	  same	  as	  above	  
Day	  6:	  same	  as	  above	  
Day	  7:	  same	  as	  above	  
	  
Weeks	  2	  onwards:	  Morning	  (take	  1	  scoop	  mixed	  with	  liquid),	  Tea	  time	  (take	  1	  scoop	  mixed	  with	  
liquid)	  
	  
• Take	  your	  powder	  shake	  with	  food.	  Drink	  plenty	  of	  water	  during	  the	  day.	  The	  most	  common	  
side	  effect	  of	  taking	  these	  pills	  is	  an	  upset	  stomach.	  This	  can	  be	  avoided	  by	  taking	  your	  pills	  
with	  food	  and	  plenty	  of	  water.	  
	  
• If	  you	  miss	  a	  dose,	  take	  the	  dose	  when	  you	  remember	  but	  make	  sure	  that	  you	  leave	  at	  least	  
2	  hours	  between	  doses.	  
	  
• Try	  not	  to	  take	  your	  last	  dose	  later	  than	  6pm	  because	  sometimes	  the	  powder	  can	  have	  an	  
energising	  effect,	  which	  can	  make	  it	  difficult	  for	  you	  to	  get	  to	  sleep.	  
	  
• The	  best	  way	  to	  make	  is	  shake	  is	  to	  blend	  it	  or	  to	  mix	  the	  powder	  into	  the	  shake	  then	  add	  
the	  remainder	  of	  the	  liquid	  you	  are	  using.	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